Tl1a binding antibodies and methods of use

Abstract

Provided herein are TL1A binding proteins (e.g., antibodies that bind to TL1A) and methods of use.

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Publication Number (43) Publication Date (21) Application Number 202480052645.1 (22) Application Date 2024.08.09 (30) Priority Data 63 / 519,056 2023.08.11 US 63 / 592,535 2023.10.23 US 63 / 599,923 2023.11.16 US 63 / 604,104 2023.11.29 US 63 / 554,897 2024.02.16 US 63 / 554,916 2024.02.16 US 63 / 559,060 2024.02.28 US 63 / 559,071 2024.02.28 US (85) PCT International Application Enters National Phase Date 2026.02.10 (86) PCT International Application Application Data PCT / US2024 / 041774 2024.08.09 (87) PCT International Application Publication Data WO2025 / 038473 EN 2025.02.20 (71) Applicant Paragon Medical Corporation Address Massachusetts, USA (72) Inventors Eric Franklin Juhousam Hisham Shaheen Daniel Rios (74) Patent Agency Shenzhen Eagle Wing Intellectual Property Agency Co., Ltd. 44658 Patent Attorney Wang Yijin Ye Huanbiao (51) Int.Cl. A61K 39 / 395 (2006.01) C07K 16 / 28 (2006.01) (54) Invention Title: TL1A Binding Antibody and Method of Use (57) Abstract: This article provides TL1A binding proteins (e.g., antibodies that bind TL1A) and methods of use. Claims 22 pages, Description 179 pages, Sequence Listing (electronic publication), Drawings 26 pages, Claims amended according to Article 19 of the Treaty 22 pages, CN 121843714 A 2026.04.10 CN 1 21 84 37 14 A 1. A TL1A binding protein, wherein the TL1A binding protein comprises: a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 9, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 9, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 15, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 15The sequence comprises: a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21; a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 21, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21; (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 27, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 27; and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 33, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 4; (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 10, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 10; or a CDR3 having the amino acid sequence according to ... The sequence NO: 10 includes (iii) a CDR2 having one or two amino acid substitutions compared to (ii) the amino acid sequence according to (iii) SEQ ID NO: 16, or a CDR3 having one or two amino acid substitutions compared to (iv) the sequence according to (ii) SEQ ID NO: 28, or a CDR2 having one or two amino acid substitutions compared to (iv) the sequence according to (iii) SEQ ID NO: 10; or a heavy chain variable region (VH) including (i) a CDR1 having one or two amino acid substitutions compared to (iv) the amino acid sequence according to (ii) SEQ ID NO: 28; and (iii) a CDR3 having one or two amino acid substitutions compared to (iv) the amino acid sequence according to (iii) SEQ ID NO: 10; or a heavy chain variable region including (i) a CDR2 having one or two amino acid substitutions compared to (iv) the amino acid sequence according to (iv) SEQ ID NO: 10; and (iii) a CDR3 having one or two amino acid substitutions compared to (iv) the amino acid sequence according to (iv) SEQ ID NO: 10; or a heavy chain variable region including (ii) a CDR2 having one or two amino acid substitutions compared to (iv) the amino acid sequence according to (iv) SEQ ID NO: 10; or ... (ii) CDR1 of the amino acid sequence according to SEQ ID NO: 5, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 5; (iii) CDR2 of the amino acid sequence according to SEQ ID NO: 11, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11; and (iii) CDR3 of the amino acid sequence according to SEQ ID NO: 17, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 17; andA light chain variable region (VL), comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 23, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 29, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 29, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 35, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 35; or a heavy chain variable region (VH), comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 6, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 6, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR1 having the amino acid sequence according to SEQ ID NO: 12, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iv ... and (iv) a CDR1 having one or two amino The sequence comprises (i) a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 18, or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 18; and a light chain variable region (VL) comprising (i) a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 24, or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 24, (ii) a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 30, or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 30, and (iii) a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 36, or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 30. The sequence 36 is compared to a CDR3 having one or two amino acid substitutions; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 7, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 7, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 19, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 19.The sequence 19 is compared to a CDR3 having one or two amino acid substitutions; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 25, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 25, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 31, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 37, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 37; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 8, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 8, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 19; or a heavy chain variable region ...19, and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 19; or a heavy chain variable region comprising The following are considered as follows: (i) CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 20; and a light chain variable region (VL) comprising (i) CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 26, (ii) CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 32, and (iii) CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 38; or a heavy chain variable region (VH) comprising (i) CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 20; or a heavy chain variable region (VH) comprising (i) CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 20; or a heavy chain variable region ...14, and (iii) CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iv) CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14, (ii) CDR1 of the amino acid sequence according to SEQ ID NO: 11, or CDR2 of the amino acid sequence according to SEQ ID NO: 11, or CDR2 of the amino acid sequence according to SEQ ID NO: 11, or CDR3 of the amino acid sequence according to SEQ ID NO: 21, or CDR3 of the amino acid sequence according to SEQ ID NO: 21, or CDR3 of the amino acid sequence according to SEQ ID NO: 21, or CDR3 of the amino acid sequence according to SEQ ID NO: 21; andA light chain variable region (VL), comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 31, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 41, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 41, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 51, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 51; or a heavy chain variable region (VH), comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 2, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 2, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR1 having the amino acid sequence according to SEQ ID NO: 12, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iv ... one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iv) a CDR The sequence comprises (i) a CDR1 having one or two amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 32, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32; and a light chain variable region (VL) comprising (i) a CDR1 having one or two amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 32, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, (ii) a CDR2 having one or two amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 42, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 42, and (iii) a CDR3 having one or two amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 52, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 52; and (iii) a light chain variable region comprising (i) a CDR1 having one or two amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 32, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 42, and (iii) a CDR3 having one or two amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 52. The sequence 52 is compared to a CDR3 having one or two amino acid substitutions; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 23, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23.The sequence 23 has a CDR3 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 33; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 33, or a CDR1 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 33, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 43, or a CDR2 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 43, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 53, or a CDR3 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 53; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR3 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 53; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR2 ... The following are considered as follows: (i) CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 34, or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 24; and a light chain variable region (VL) comprising (i) CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 34, (ii) CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 44, or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 44, and (iii) CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 54; or a heavy chain variable region (VH) comprising (i) CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14, or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 54; and (iii) CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 54; or a heavy chain variable region (VH) comprising (i) CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14, or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14; and (iii) CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14; or (iv) CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 14; or (viii ... (ii) CDR1 of the amino acid sequence according to SEQ ID NO: 321, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) CDR3 of the amino acid sequence according to SEQ ID NO: 539, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 539, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iv) CDR3 having the amino acid sequence according to SEQ ID NO: 539, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iv) CDR2 having one or two amino acid substitutions compared to the sequence of SEQThe sequence 539 is compared to a CDR3 having one or two amino acid substitutions; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 648, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 648, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 757, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 757, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 866, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 866; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 341, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 341, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 648, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 648, and (iv) a CDR3 having the amino acid sequence according to SEQ ID NO: 648, and (viii ... The CDR2 of the amino acid sequence of SEQ ID NO: 450, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 559, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 559; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence of SEQ ID NO: 668, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 668, (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 777, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 777, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 886, or a CDR2 having one or two amino acid substitutions compared to the ...2 having the amino acid sequence of SEQ ID NO: 886, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 886, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 886, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 886, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID The sequence of 886 is compared to a CDR3 having one or two amino acid substitutions; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 345, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 345, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 454, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 454, and (iii) having the sequence according to SEQ ID NO: 345.The CDR3 of the amino acid sequence of SEQ ID NO: 563, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 563; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence of SEQ ID NO: 672, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 672, (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 781, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 781, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 890, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 890; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence of SEQ ID NO: 349, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 563; The sequence comprises (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 458, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 458, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 567; and a light chain variable region (VL) comprising (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 676, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 676, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 785, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 785, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 894 ... CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 894; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 351, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 351, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 460, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 460, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 894.The CDR3 of the amino acid sequence of SEQ ID NO: 569, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 569; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence of SEQ ID NO: 678, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 678, (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 787, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 787, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 896, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 896; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence of SEQ ID NO: 354, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 569; The following are descriptions of CDR1 and CDR2: (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 463, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 463; and (iii) CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 572; and (iii) a light chain variable region (VL) comprising (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 681, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 681, (ii) CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 790, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 790; and (iii) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 790. The CDR3 having the amino acid sequence according to SEQ ID NO: 899, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 899; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 365, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 365, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 474, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 899; or a heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 365, or a CDR2 ...365, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 365, (ii) a CDR3 having the amino acid sequence according to SEQ ID NO: 365, (ii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 365, (ii) a CDR3 having the amino acid sequence according to SEQ ID NO: 365, (ii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ IDThe sequence 474 is compared to CDR2 having one or two amino acid substitutions, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 583, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 583; and a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 692, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 692, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 801, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 801, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 910, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 910; or a heavy chain variable region (VH) comprising (i) having the amino acid sequence according to SEQ ID NO: The amino acid sequence of SEQ ID NO: 371, CDR1, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 371; (ii) CDR2 having the amino acid sequence of SEQ ID NO: 480, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 480; and (iii) CDR3 having the amino acid sequence of SEQ ID NO: 589, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 589; and a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence of SEQ ID NO: 698, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 698; (ii) CDR2 having the amino acid sequence of SEQ ID NO: 807, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 807; and (iii) CDR3 having the amino acid sequence of SEQ ID NO: 589; and (iii) CDR2 having the amino acid sequence of SEQ ID NO: 698; and (iv) CDR2 having the amino acid sequence of SEQ ID NO: 807; and (iv) CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 807; and (iv) CDR2 having the amino acid sequence of SEQ ID NO: 698 ...698; and (iv) CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 698; and (iv) CDR2 having one or two amino acid substitutions compared to the sequence of SEQ CDR3 of the amino acid sequence of SEQ ID NO: 916, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 916; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 372, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 372, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 481, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 916; or a heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 481, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 916; or a heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 916, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 916; or a heavy chain variable region comprising (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 481, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 916; or a heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 481, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 916; or a heavy chain variable region comprising (ii) a CDR2 ...The sequence 481 is compared to CDR2 having one or two amino acid substitutions, and (iii) has CDR3 having the amino acid sequence according to SEQ ID NO: 590, or has CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 590; and a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 691, or has CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 691, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 808, or has CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 808, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 917, or has CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 917; or a heavy chain variable region (VH) comprising (i) having the amino acid sequence according to SEQ ID NO: The CDR1 of the amino acid sequence of SEQ ID NO: 373, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 373, (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 482, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 482, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 591, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 591; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence of SEQ ID NO: 700, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 700, (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 809, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) a CDR2 having the amino acid sequence of SEQ ID NO: 809, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iv ... one or two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 80 The sequence of 809 includes (iii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918; or a heavy chain variable region (VH) comprising (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 388, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 388, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918; or a heavy chain variable region comprising (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 388, or a CDR3 ...ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918; or a heavy chain variable region comprising (iii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918; or a heavy chain variable region comprising (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 388, or a CDR3 having one or two amino acid substitutionThe CDR2 of the amino acid sequence according to SEQ ID NO: 497, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 497, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 606, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 606; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 715, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 715, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 824, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 824, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 933, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 497, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 933, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 497, and (iii) a CDR2 ... The sequence 933 is compared to a CDR3 having one or two amino acid substitutions; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 394, or a CDR1 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 394, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 503, or a CDR2 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 503, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 612, or a CDR3 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 612; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 721, or a CDR1 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 721, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 933, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 933, (iv) a CDR3 having the amino acid sequence according to SEQ ID NO: 933, (viii ... The CDR2 of the amino acid sequence of SEQ ID NO: 830, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 830, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 939, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 939; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence of SEQ ID NO: 400, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 400, (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 830, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 939; and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 939, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 939; or a heavy chain variable region comprising (i) a CDR1 having the amino acid sequence of SEQ ID NO: 400, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 400, and (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 930, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 930; and (iii) a CDR2 having the amino acid sequence of SEQ ID NO: 939, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 930; or a CDR2 having the amino acid sequence of SEQ ID NO: 930 ...The CDR2 of the amino acid sequence of SEQ ID NO: 509, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 509, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 618, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 618; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence of SEQ ID NO: 727, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 727, (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 836, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 836, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 945, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 945. 2. The TL1A binding protein of claim 1, wherein the TL1A binding protein comprises: a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 9, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 15; and a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 21, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 27, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 33; or a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 9, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 15; and a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 9, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 15; and a light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 9, (ii) a CDR2 ...15; and a light chain variable region comprising (i) a CDR1 having (iii) having a CDR2 of the amino acid sequence of SEQ ID NO: 10, and (iii) having a CDR3 of the amino acid sequence of SEQ ID NO: 16; and a light chain variable region (VL) comprising (i) having a CDR1 of the amino acid sequence of SEQ ID NO: 22, (ii) having a CDR2 of the amino acid sequence of SEQ ID NO: 28, and (iii) having a CDR3 of the amino acid sequence of SEQ ID NO: 34; or a heavy chain variable region (VH) comprising (i) having a CDR1 of the amino acid sequence of SEQ ID NO: 10, and (iii) having a CDR3 of the amino acid sequence of SEQ ID NO: 16; and a light chain variable region comprising (i) having a CDR2 of the amino acid sequence of SEQ ID NO: 10, and (iii) having a CDR3 of the amino acid sequence of SEQ ID NO: 16; and a light chain variable region comprising (i) having a CDR1 of the amino acid sequence of SEQ ID NO: 22, (ii) having a CDR2 of the amino acid sequence of SEQ ID NO: 28, and (iii) having a CDR3 of the amino acid sequence of SEQ ID NO: 34; or a heavy chain variable region comprising (i) having a CDR1 of the amino acid sequence of SEQ ID NO: 10, and (iii) having a CDR3 of the amino acid sequence of SEQ ID NO: 16; and a light ...The amino acid sequence of 5 has CDR1, (ii) has CDR2 according to the amino acid sequence of SEQ ID NO: 11, and (iii) has CDR3 according to the amino acid sequence of SEQ ID NO: 17; and a light chain variable region (VL) comprising (i) has CDR1 according to the amino acid sequence of SEQ ID NO: 23, (ii) has CDR2 according to the amino acid sequence of SEQ ID NO: 29, and (iii) has CDR3 according to the amino acid sequence of SEQ ID NO: 35; or a heavy chain variable region (VH) comprising (i) has CDR1 according to the amino acid sequence of SEQ ID NO: 6, (ii) has CDR2 according to the amino acid sequence of SEQ ID NO: 12, and (iii) has CDR3 according to the amino acid sequence of SEQ ID NO: 18; and a light chain variable region (VL) comprising (i) has CDR1 according to the amino acid sequence of SEQ ID NO: 11, (ii) has CDR2 according to the amino acid sequence of SEQ ID NO: 11, and (iii) has CDR3 according to the amino acid sequence of SEQ ID NO: 17. The CDR1 of the amino acid sequence 24, (ii) having the CDR2 of the amino acid sequence according to SEQ ID NO: 30, and (iii) having the CDR3 of the amino acid sequence according to SEQ ID NO: 36; or the heavy chain variable region (VH), which comprises (i) having the CDR1 of the amino acid sequence according to SEQ ID NO: 7, (ii) having the CDR2 of the amino acid sequence according to SEQ ID NO: 13, and (iii) having the CDR3 of the amino acid sequence according to SEQ ID NO: 19; and the light chain variable region (VL), which comprises (i) having the CDR1 of the amino acid sequence according to SEQ ID NO: 25, (ii) having the CDR2 of the amino acid sequence according to SEQ ID NO: 31, and (iii) having the CDR3 of the amino acid sequence according to SEQ ID NO: 37; or the heavy chain variable region (VH), which comprises (i) having the CDR1 of the amino acid sequence according to SEQ ID NO: 25, (ii) having the CDR2 of the amino acid sequence according to SEQ ID NO: 31, and (iii) having the CDR3 of the amino acid sequence according to SEQ ID NO: 37; The amino acid sequence of 8 has CDR1, (ii) has CDR2 according to the amino acid sequence of SEQ ID NO: 14, and (iii) has CDR3 according to the amino acid sequence of SEQ ID NO: 20; and a light chain variable region (VL) comprising (i) has CDR1 according to the amino acid sequence of SEQ ID NO: 26, (ii) has CDR2 according to the amino acid sequence of SEQ ID NO: 32, and (iii) has CDR3 according to the amino acid sequence of SEQ ID NO: 38; or a heavy chain variable region (VH) comprising (i)The CDR1 having the amino acid sequence according to SEQ ID NO: 1, (ii) the amino acid sequence according to SEQ ID NO: 11, and (iii) the amino acid sequence according to SEQ ID NO: 21; and a light chain variable region (VL) comprising (i) the amino acid sequence according to SEQ ID NO: 31, (ii) the amino acid sequence according to SEQ ID NO: 41, and (iii) the amino acid sequence according to SEQ ID NO: 51; or a heavy chain variable region (VH) comprising (i) the amino acid sequence according to SEQ ID NO: 2, (ii) the amino acid sequence according to SEQ ID NO: 12, and (iii) the amino acid sequence according to SEQ ID NO: 12. CDR3 of the amino acid sequence of SEQ ID NO: 22; and a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence of SEQ ID NO: 32, (ii) CDR2 having the amino acid sequence of SEQ ID NO: 42, and (iii) CDR3 having the amino acid sequence of SEQ ID NO: 52; or a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence of SEQ ID NO: 3, (ii) CDR2 having the amino acid sequence of SEQ ID NO: 13, and (iii) CDR3 having the amino acid sequence of SEQ ID NO: 23; and a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence of SEQ ID NO: 33, (ii) CDR2 having the amino acid sequence of SEQ ID NO: 43, and (iii) CDR3 having the amino acid sequence of SEQ ID NO: 52; CDR3 having the amino acid sequence of SEQ ID NO: 53; or heavy chain variable region (VH), the heavy chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 4, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 14, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 24; and light chain variable region (VL), the light chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 34, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 44, and (iii)The region may contain: a CDR3 having the amino acid sequence according to SEQ ID NO: 54; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 321, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 430, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 539; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 648, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 757, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 866; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 341, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 450, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 450. The region comprises: a CDR3 having the amino acid sequence according to SEQ ID NO: 559; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 668, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 777, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 886; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 345, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 454, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 563; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 672, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 781, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 781. The heavy chain variable region (VH) comprises (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 349, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 458, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 567; and a light chain variable region (VL) comprising...(i) a CDR1 having the amino acid sequence according to SEQ ID NO: 676, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 785, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 894; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 351, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 460, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 569; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 678, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 787, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 894. CDR3 of the amino acid sequence 896; or heavy chain variable region (VH), the heavy chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 354, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 463, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 572; and light chain variable region (VL), the light chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 681, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 790, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 899; or heavy chain variable region (VH), the heavy chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 365, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 474, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 899. CDR3 having the amino acid sequence of SEQ ID NO: 583; and a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 692, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 801, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 910; or a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 371, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 480, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 583.CDR3 having the amino acid sequence according to SEQ ID NO: 589; and a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 698, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 807, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 916; or a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 372, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 481, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 590; and a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 691, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 807, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 589; CDR3 of the amino acid sequence according to SEQ ID NO: 917; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 373, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 482, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 591; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 700, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 809, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 918; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 38 ...3 having the amino acid sequence according to SEQ ID NO: 917; or a heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 388, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 482, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 591; or a light chain variable region comprising (i) a CDR1 having the CDR2 having the amino acid sequence of SEQ ID NO: 497, and (iii) CDR3 having the amino acid sequence of SEQ ID NO: 606; and a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence of SEQ ID NO: 715, (ii) CDR2 having the amino acid sequence of SEQ ID NO: 824, and (iii) CDR3 having the amino acid sequence of SEQ ID NO: 933; or a heavy chain variable region (VH) comprising (i)The region comprises: (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 394; (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 503; and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 612; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 721; (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 830; and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 939; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 400; (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 509; and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 618; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 394; (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 503 ...H) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 394; (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 503; and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 612; and a light chain variable region (VH) comprising (i) (ii) CDR1 having the amino acid sequence according to SEQ ID NO: 727, (iii) CDR2 having the amino acid sequence according to SEQ ID NO: 836, and (iv) CDR3 having the amino acid sequence according to SEQ ID NO: 945. 3. The TL1A binding protein of claim 1 or claim 2, wherein the TL1A binding protein comprises an immunoglobulin Fc domain. 4. A TL1A binding protein comprising: (a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 3-8, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 3-8, (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NO: 9-14, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 9-14, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 15-20, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 15-20; and (b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 3-8, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 3-8; and (iii) a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 3-8; and (iv) a light chain variable region comprising (i) ...iv) a light chain variable region comprising (i) a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 3-8; and (iv) a light chain variable region comprising ( (ii) CDR1 having an amino acid sequence of any one of SEQ ID NO: 21-26, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 21-26,(iii) A CDR2 having an amino acid sequence according to any one of SEQ ID NO: 27-32, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 27-32, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 33-38, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 33-38. 5. The TL1A binding protein of claim 4, wherein the VH comprises a sequence having at least 80% sequence identity with an amino acid sequence of any one of SEQ ID NO: 111-116, and the VL comprises a sequence having at least 80% sequence identity with an amino acid sequence of any one of SEQ ID NO: 117-122. 6. The TL1A binding protein of claim 4 or claim 5, wherein the VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 111, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 117, wherein the VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 112, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 118, wherein the VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 113, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 119, wherein the VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 114, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 119. The amino acid sequence of SEQ ID NO: 120 has at least 80% sequence identity, wherein the VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 115, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 121, or wherein the VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 116, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 122. 7. A TL1A binding protein, wherein the TL1A binding protein comprises: a heavy chain variable region (VH), wherein the heavy chain variable region comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, or a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 122.The following are CDR1 sequences compared to SEQ ID NO: 3, having one or two amino acid substitutions: (ii) CDR2 sequences according to SEQ ID NO: 9, or CDR2 sequences with one or two amino acid substitutions compared to SEQ ID NO: 9; and (iii) CDR3 sequences according to SEQ ID NO: 15, or CDR3 sequences with one or two amino acid substitutions compared to SEQ ID NO: 15; and a light chain variable region (VL) comprising (i) CDR1 sequences according to SEQ ID NO: 21, or CDR1 sequences with one or two amino acid substitutions compared to SEQ ID NO: 21; (ii) CDR2 sequences according to SEQ ID NO: 27, or CDR2 sequences with one or two amino acid substitutions compared to SEQ ID NO: 27; and (iii) CDR3 sequences according to SEQ ID NO: 3, or CDR2 sequences with one or two amino acid substitutions compared to SEQ ID NO: 3; and (iii) CDR3 sequences according to SEQ ID NO: 3, or CDR2 sequences with one or two amino acid substitutions compared to SEQ ID NO: 3. The sequence 33 is compared to a CDR3 having one or two amino acid substitutions; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 10, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 10, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 16, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 16; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 22, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 28, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 22, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 28, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 28, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 22, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 28, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 34, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 34; or heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 5, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 28;The sequence comprises (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 17; and a light chain variable region (VL) comprising (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 29, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 29, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 17; and (iii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 17. The CDR3 of the amino acid sequence of SEQ ID NO: 35, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 35; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 6, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 6, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 18, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 18; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 24, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 24, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 25, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 18, (iv) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 24, (viii) a CDR1 having the amino acid sequence according to SEQ ID NO: 25, (viii) a CDR2 having one or two amino acid substitutions compared to the sequence of ... CDR2 of the amino acid sequence according to SEQ ID NO: 30, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 30, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 36, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 36; or heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 7, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 30; and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 36, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 36; or heavy chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 7, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 30; and (The sequence comprises (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 7, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 19; and a light chain variable region (VL) comprising (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 25, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 25, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 7, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 7 ...2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 7, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO The sequence 37 is compared to a CDR3 having one or two amino acid substitutions; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 8, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 8, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 20, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 20; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 26, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 26, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 32, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 26, and ...iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 32, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 37; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 26, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 26, and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 32, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 37; and a light chain variable CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 38, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 38. 8. The TL1A binding protein of claim 7, wherein the TL1A binding protein comprises: a heavy chain variable region (VH), the heavy chain variable region comprising (i) having the amino acid sequence according to SEQ ID NO: 3.CDR1, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 9, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 15; and a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 21, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 27, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 33; or a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 4, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 10, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 16; and a light chain variable region (VL) comprising (i) The following are considered amino acid sequences: (i) CDR1 having the amino acid sequence according to SEQ ID NO: 22, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 28, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 34; or a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 22, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 11, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 17; and a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 23, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 29, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 35; or a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 22, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 28, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 34. The amino acid sequence of 6 has CDR1, (ii) has CDR2 according to the amino acid sequence of SEQ ID NO: 12, and (iii) has CDR3 according to the amino acid sequence of SEQ ID NO: 18; and a light chain variable region (VL) comprising (i) CDR1 according to the amino acid sequence of SEQ ID NO: 24, (ii) CDR2 according to the amino acid sequence of SEQ ID NO: 30, and (iii) CDR3 according to the amino acid sequence of SEQ ID NO: 18.CDR3 of the amino acid sequence 36; or heavy chain variable region (VH), the heavy chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 7, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 13, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 19; and light chain variable region (VL), the light chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 25, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 31, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 37; or heavy chain variable region (VH), the heavy chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 8, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 14, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 19. The CDR3 having an amino acid sequence of SEQ ID NO: 20; and a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 26, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 32, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 38. 9. A TL1A binding protein comprising a heavy chain variable region (VH), the heavy chain variable region comprising: (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 3-8, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 3-8; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NO: 9-14, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 9-14; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 15-20, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 15-20. 10. A TL1A binding protein comprising a light chain variable region (VL), the light chain variable region comprising: (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 21-26, or having an amino acid sequence according to SEQ ID NO:(ii) CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 27-32; or CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 27-32; and (iii) CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 33-38. 11. The TL1A binding protein of any one of claims 1-8, wherein the TL1A binding protein is an antibody having an IgG1, IgG2, or IgG4 immunoglobulin Fc domain. 12. The TL1A binding protein of claim 11, wherein the Fc domain is a modified Fc that prolongs the half-life of the TL1A binding protein compared to a TL1A binding protein not containing the modified Fc domain. 13. The TL1A binding protein of claim 11 or claim 12, wherein the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE). 14. A TL1A binding antibody, wherein the TL1A binding antibody specifically binds to a TL1A polypeptide comprising SEQ ID NO: 2493 at any one of the following amino acid residues: Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123, and Arg 156. 15. The TL1A binding antibody of claim 14, wherein the TL1A binding antibody specifically binds to the TL1A sequence at the amino acid residues Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123, and Arg 156. 16. The TL1A binding protein or TL1A binding antibody according to any one of claims 1-15, wherein the TL1A binding protein binds TL1A with a KD of less than about 0.5 nanomolar (nM). 17. A TL1A binding protein comprising: a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 1-4 and 313-421, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 1-4 and 313-421, and (ii) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 11-14 and 422-530.The CDR2 of an amino acid sequence according to SEQ ID NO: 11-14 and 422-530, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 11-14 and 422-530, and (iii) having an amino acid sequence according to SEQ ID NO: 21-24 and 531-639, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 21-24 and 531-639; and b) a light chain variable region (VL) comprising (i) a CDR1 of an amino acid sequence according to SEQ ID NO: 31-34 and 640-748, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 1-4 and 313-421, and (ii) having an amino acid sequence according to SEQ ID NO: 11-14 and 422-530. CDR2 having an amino acid sequence of any one of SEQ ID NO: 41-44 and 749-857, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 41-44 and 749-857, and (iii) having an amino acid sequence of any one of SEQ ID NO: 51-54 and 858-966, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 51-54 and 858-966. 18. The TL1A binding protein of claim 17, wherein the VH comprises a sequence having at least 80% sequence identity with an amino acid sequence of any one of SEQ ID NO: 181-184 and 2275-2383, and the VL comprises a sequence having at least 80% sequence identity with an amino acid sequence of any one of SEQ ID NO: 191-194 and 2384-2492. Claims 14 / 22, page 15, CN 121843714, A 19. The TL1A binding protein of claim 17 or claim 18, wherein the VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 181, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 191; the VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 182, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 192; the VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 183, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 183.The amino acid sequence of SEQ ID NO: 193 has at least 80% sequence identity; the VH contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 184, and the VL contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 194; the VH contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2283, and the VL contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2392; the VH contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2303, and the VL contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2412; the VH contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2307, and the VL contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2416 ... The amino acid sequence of SEQ ID NO: 2311 has at least 80% sequence identity, and the VL contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2420; the VH contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2313, and the VL contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2422; the VH contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2316, and the VL contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2425; the VH contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2327, and the VL contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2436; the VH contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2333, and the VL contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2420. The amino acid sequence of NO: 2442 has at least 80% sequence identity; the VH contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2334, and the VL contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2443; the VH contains a sequence with at least 80% sequence identity to the amino acid sequence of SEQ ID NO: 2335, and theThe VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2444; the VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2350, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2459; the VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2356, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2465; or the VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2362, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2471. 20. A TL1A binding protein comprising: a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 1, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 1, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 21, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21; and a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 31, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 1, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11; and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 21, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11; and (iv) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11; and (iv) a CDR3 ... The following are possible sequences of SEQ ID NO: 31: (ii) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 41, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 41, and (iii) CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 51; or heavy chain variable region (VH) comprising (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 2, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 2, (ii) CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 51; or heavy chain variable region (VH) comprising (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 2, (ii) CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 41.The following are considered as follows: (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32; and a light chain variable region (VL) comprising (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, (ii) CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 42, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 42, and (iii) CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 52; or a heavy chain variable region (VH) comprising (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, or CDR2 ... comprising (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12; or a heavy chain variable region comprising (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12; or a heavy chain variable region comprising (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12; or a heavy chain variable region comprising (i) CDR1 having one The CDR1 of the amino acid sequence of SEQ ID NO: 3, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 23, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence of SEQ ID NO: 33, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33, (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 43, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 43, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 33, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 43, and (iii) a CDR2 ... CDR3 of the amino acid sequence of SEQ ID NO: 53, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 53; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 4, and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 14.(iii) an acid-substituted CDR2, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 24, or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 24; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 34, or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 34, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 44, or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 44, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 54, or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 54; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 321, or a CDR2 ... The sequence 321 comprises (ii) a CDR1 having one or two amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 430, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) a CDR3 having one or two amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 539; and a light chain variable region (VL) comprising (i) a CDR1 having one or two amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 648, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 648, (ii) a CDR2 having one or two amino acid substitutions compared to the amino acid sequence of SEQ ID NO: 757, and (iii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 757. The CDR3 having the amino acid sequence according to SEQ ID NO: 866, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 866; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 341, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 341, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 450, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 866; or a heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 341, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 341; or a CDR2 having the amino acid sequence according to SEQ ID NO: 450; or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 866; or a heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 341, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 341; or a heavy chain variable region comprising (ii) ...The following are considered as follows: (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iii) CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 559; and a light chain variable region (VL) comprising (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 668, (ii) CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 777, and (iii) CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 886; or a heavy chain variable region (VH) comprising (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iii) CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 886; or a heavy chain variable region (VH) comprising (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iii) CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450; and (iv) CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450; and (viii ... The CDR1 of the amino acid sequence according to SEQ ID NO: 345, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 345, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 454, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 454, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 563, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 563; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 672, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 672, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 781, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 781, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 345 ... CDR3 of the amino acid sequence of SEQ ID NO: 890, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 890; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 349, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 349, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 458, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 890; or a heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 349, or CDR3 ...890; or a heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 458, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 890; or a heavy chain variable region comprising (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 458, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 890; or a heavy chain variable region comprising (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 458, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 890; or a heavy chain variable region comprising (ii) aThe following are considered as CDRs: (i) CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 458, or CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 567; and a light chain variable region (VL) comprising (i) CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 676, or CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 676, (ii) CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 785, or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 785, and (iii) CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 894; or a heavy chain variable region (VH) comprising (i) CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 458, or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 458; and (iii) CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 894; or a heavy chain variable region (VH) comprising (i) CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 458, or CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 458; and (iii) CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 458. The amino acid sequence of SEQ ID NO: 351, page 17 / 22 of claim 18, CN 121843714 A, includes: (ii) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 351; (iii) a CDR2 having the amino acid sequence of SEQ ID NO: 460, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 460; and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 569, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 569; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence of SEQ ID NO: 678, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 678; (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 787, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 678; and (iii) a CDR2 having the amino acid sequence of SEQ ID NO: 787, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 678; and (iv) a CDR2 having the amino acid sequence of SEQ ID NO: 787; or (v) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 678; and (v) a CDR2 having the amino acid sequence of SEQ ID NO: 787; or (v) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 678; and ... The sequence 787 is compared to CDR2 having one or two amino acid substitutions, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 896, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 896; or a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 354, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 354, (ii) having root(ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 463, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 463, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 572, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 572; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 681, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 681, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 790, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 790, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 899, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 899, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 899, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 899, and (iv ... one or two amino acid substitutions compared to the sequence of SEQ ID NO: 899, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 899, and (iv) a CDR2 having one or two amino acid substitutions compared The sequence 899 is compared to a CDR3 having one or two amino acid substitutions; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 365, or a CDR1 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 365, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 474, or a CDR2 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 474, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 583, or a CDR3 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 583; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 692, or a CDR1 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 692, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 692, (iii) a CDR1 having the amino acid sequence according to SEQ ID NO: 692, (iv) a CDR1 having one or two amino acid substitutions compared to the sequence SEQ ID NO: 692, (viii) a CDR1 having the amino acid sequence according to ... The CDR2 of the amino acid sequence of SEQ ID NO: 801, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 801, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 910, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 910; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 371, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 371, (ii) having a rootCDR2 according to the amino acid sequence of SEQ ID NO: 480, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 480, and (iii) CDR3 according to the amino acid sequence of SEQ ID NO: 589, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 589; and a light chain variable region (VL) comprising (i) CDR1 according to the amino acid sequence of SEQ ID NO: 698, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 698, (ii) CDR2 according to the amino acid sequence of SEQ ID NO: 807, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 807, and (iii) CDR3 according to the amino acid sequence of SEQ ID NO: 916, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 916, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 916, and ... The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 372, or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 372, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 481, or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 481, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 590, or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 590; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 691, or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 590; The following are possible alternatives to the sequence 691: (ii) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 808, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 808, and (iii) CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 917; or heavy chain variable region (VH) comprising (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 373, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 691; or heavy chain variable region comprising (i) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 373, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 691.The sequence comprises (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 700, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 700, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 809, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918; and a light chain variable region (VL) comprising (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 700, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918; and a light chain variable region comprising (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 700, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918; and a light chain variable region comprising (ii) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 700, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918; and a light chain variable region comprising The sequence NO: 918 is compared to a CDR3 having one or two amino acid substitutions; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 388, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 388, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 497, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 497, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 606, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 606; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 715, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 715, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 918, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 918, (iv) a CDR3 having the amino acid sequence according to SEQ ID NO: 918, (viii) a CDR3 having the amino acid sequence according to SEQ ID NO: 918, (viii) a CDR3 having the amino acid sequence according to SEQ ID NO: 918, (viv ... The CDR2 of the amino acid sequence of SEQ ID NO: 824, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 824, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 933, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 933; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 394, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 824, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 933, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 933; or a heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 394, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 933, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 933, or a CDR2 ...2 having the amino acid sequence according to SEQ ID NO: 934, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 933, and (iii) a CDR2 having the aminoThe sequence comprises (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 830, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 830, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 939, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 612; and a light chain variable region (VL) comprising (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 830, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 830, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 939, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 939; and (iii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 939. Claims 19 / 22 pages 20 CN 121843714 A NO: 939 A CDR3 having one or two amino acid substitutions compared to the sequence; or a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 400, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 400, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 509, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 509, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 618, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 618; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 727, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 939; The sequence of 727 is compared to CDR1 having one or two amino acid substitutions, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 836, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 836, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 945, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 945.21. A TL1A binding protein comprising a heavy chain variable region (VH), the heavy chain variable region comprising: (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 1-4 and 313-421, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 1-4 and 313-421; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NO: 11-14 and 422-530, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 11-14 and 422-530; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 21-24 and 531-639, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 11-14 and 422-530; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 11-24 and 531-639, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 11-14 and 422-530; and (iv) ... CDR3 is an amino acid sequence with one or two amino acid substitutions compared to any one of 21-24 and 531-639. 22. A TL1A binding protein comprising a light chain variable region (VL), the light chain variable region comprising: (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 31-34 and 640-748, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 31-34 and 640-748; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NO: 41-44 and 749-857, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 41-44 and 749-857; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 51-54 and 858-966, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 31-34 and 640-748 ...iv) a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 31-34 and 640-748; and (iv) a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 31-34 and 640-748; and (iv) a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 31-34 and 640-748; and (iv) a CDR2 having an amino acid CDR3 having one or two amino acid substitutions compared to any one of 51-54 and 858-966. 23. The TL1A binding protein of any one of claims 17-20, wherein the TL1A binding protein is an antibody, the antibody comprising an IgG1, IgG2, or IgG4 immunoglobulin Fc domain. 24. The TL1A binding protein of claim 23, wherein the Fc domain is a modified Fc, the modified Fc extending the half-life of the TL1A binding protein compared to a TL1A binding protein not containing the modified Fc domain. 25. The TL1A binding protein of claim 24, wherein the modified Fc domain comprises amino acid modifications.L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE). Claims 20 / 22, page 21, CN 121843714, A 26. A TL1A binding antibody, wherein the TL1A binding antibody specifically binds to a TL1A polypeptide comprising SEQ ID NO: 2493 at any one of the following amino acid residues: Lys243, Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Ile233, Asp232, Met158, Arg156, Trp119, His118, Lys111, Phe110, His109, Gln108, Thr107, Pro106, Thr105, Gln104, Arg103, Val102, and Val101. 27. A TL1A binding antibody, wherein the TL1A binding antibody specifically binds to a TL1A polypeptide comprising SEQ ID NO: 2493 at any one of the following amino acid residues: Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Gln104, and Arg103. 28. The TL1A binding protein according to any one of claims 17-27, wherein the TL1A binding protein binds TL1A with a KD of less than about 0.5 nanomolars (nM). 29. A method of treating an inflammatory disease in a patient in need, the method comprising administering, subcutaneously or intravenously, to the patient an effective amount of a TL1A-binding protein as described in any one of claims 1-28, or a TL1A-binding antibody specifically binding to a TL1A polypeptide comprising SEQ ID NO: 2493 at any one of the following amino acid residues: Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Gln104, and Arg103, or a TL1A-binding antibody specifically binding to a TL1A polypeptide comprising SEQ ID NO: 2493 at any one of the following amino acid residues: Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123, and Arg 156. 30. The method of claim 29, wherein the inflammatory disease is a gastrointestinal inflammatory disease or inflammatory bowel disease. 31. The method of claim 30, wherein the inflammatory bowel disease is Crohn's disease. 32. The method of claim 31, wherein the inflammatory bowel disease is ulcerative colitis. 33. The method of claim 32, wherein the inflammatory disease is psoriasis, psoriatic arthritis, or hidradenitis suppurativa.34. The method of any one of claims 29-33, wherein the administration of the TL1A binding protein is subcutaneous. 35. The method of any one of claims 29-33, wherein the administration of the TL1A binding protein is intravenous. 36. The method of any one of claims 29-33, the method comprising administering the TL1A binding protein to the patient two or more times at intervals of about 2 weeks to about 12 weeks or longer. 37. A composition comprising the TL1A binding protein of any one of claims 1-28 and a pharmaceutically acceptable carrier. 38. An injectable liquid composition comprising the TL1A binding protein of any one of claims 1-28 and a pharmaceutically acceptable carrier. 39. An isolated nucleic acid encoding the TL1A binding protein of any one of claims 1-28. 40. A recombinant host cell comprising the isolated nucleic acid of claim 39. 41. A method for producing a TL1A binding protein, wherein the TL1A binding protein specifically binds to a TL1A polypeptide comprising SEQ ID NO: 2493 at any one of the amino acid residues in Table 12, 13, or 14, wherein the TL1A antigen-binding protein is an antibody. 42. The method of claim 41, wherein the TL1A binding antibody specifically binds to the TL1A polypeptide comprising SEQ ID NO: 2493 at any one of the following amino acid residues: Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Gln104, and Arg103. 43. The method of claim 41, wherein the TL1A binding antibody specifically binds to the TL1A polypeptide comprising SEQ ID NO: 2493 at any one of the following amino acid residues: Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123, and Arg 156. 44. A method for obtaining an antibody that specifically binds to certain epitope portions of a TL1A sequence comprising SEQ ID NO: 2493 or SEQ ID NO: 2494, wherein the method comprises: a) assessing whether the antibody specifically binds to the certain epitope portions, wherein the certain epitope portions i) are recognized by the antibody as described in any one of claims 1-28; or ii) have the amino acid residues Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123, and Arg 156 of SEQ ID NO: 2493.156, or iii) having amino acid residues Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Gln104, and Arg103 of SEQ ID NO: 2493, and b) separating or selecting the antibody that binds to the said epitope moieties. Claims 22 / 22 pages 23 CN 121843714 A TL1A binding antibody and method of use Cross-reference to related applications

[0001] This application claims the benefit and priority of the following applications: U.S. Provisional Application No. 63 / 519,056, filed August 11, 2023; U.S. Provisional Application No. 63 / 592,535, filed October 23, 2023; U.S. Provisional Application No. 63 / 599,923, filed November 16, 2023; and U.S. Provisional Application No. 63 / 604,104, filed November 29, 2023; U.S. Provisional Application No. 63 / 554,897, filed February 16, 2024; U.S. Provisional Application No. 63 / 554,916, filed February 16, 2024; U.S. Provisional Application No. 63 / 559,060, filed February 28, 2024; and U.S. Provisional Application No. 63 / 559,071, filed February 28, 2024, the entire contents of each of which are incorporated herein by reference. Sequence List

[0002] This application contains a sequence list that has been filed electronically in XML format and is hereby incorporated by reference in its entirety. An XML copy created on August 8, 2024, is named 220703-010508_PCT_SL.xml and is 2,191,113 kilobytes in size. Background Art

[0003] Tumor necrosis factor (TNF)-like cytokine 1A (TL1A) is part of the TNF superfamily and is a transmembrane protein expressed by myeloid monocytes and endothelial cells. TL1A interacts with its receptors death receptor 3 (DR3) and decoy receptor 3 (DcR3) to trigger signal transduction. TL1A is elevated in individuals with inflammatory diseases, including Crohn's disease and ulcerative colitis, and DR3 expression is upregulated in inflamed tissues. Therefore, TL1A, along with other members of the TNF superfamily, has been investigated as a therapeutic target for the treatment of inflammatory diseases, including inflammatory bowel disease. Currently, biologics targeting TNF are associated with serious side effects, highlighting the need for improved therapies targeting TL1A. Summary of the Invention

[0004] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 3, or with SEQ ID NO:The sequence comprises (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 9, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 9, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 15; and (b) a light chain variable region (VL) comprising (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 27, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 27, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 3 ...2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 27, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 27, and (iii) a CDR3 having one or two amino The sequence 33 has one or two amino acid substitutions compared to CDR3. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having the amino acid sequence according to SEQ ID NO: 3, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 9, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 15; and b) a light chain variable region (VL), which comprises (i) CDR1 having the amino acid sequence according to SEQ ID NO: 21, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 27, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 33. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. (Page 1 / 179, CN 121843714 A) In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0005] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 4, and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 10, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 10.The CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 10, and (iii) the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 16; and b) a light chain variable region (VL) comprising (i) the CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22, (ii) the CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 28, and (iii) the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 34. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 4, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 10, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 16; and b) a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 22, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 28, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 34. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0006] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 5, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 5, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 17, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 17.The CDR3 having two amino acid substitutions; and b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 23, or a CDR1 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 23, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 29, or a CDR2 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 29, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 35, or a CDR3 having one to two amino acid substitutions compared to the sequence of SEQ ID NO: 35. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 5, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 11, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 17; and b) a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 23, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 29, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 35. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0007] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 6, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 6, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 18, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 18; and b) a light chain variable region (VL), the light chain variable region comprising (i) a heavy chain variable region having the amino acid sequence according to SEQ ID NO: 6, or a heavy chain variable region having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 6, and (iii) a heavy chain variable region having the amino acid sequence according to SEQ ID NO: 6, or a heavy chain variable region having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 6; and (iv) a heavy chain variable region having the amino acid sequence according to SEQ ID NO: 6, or a heavy chain variable region having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 6, ...(ii) CDR1 of the amino acid sequence of SEQ ID NO: 24, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 30, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 30, and (iii) CDR3 of the amino acid sequence of SEQ ID NO: 36, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 36. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 6, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 12, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 18; and b) a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 24, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 30, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 36. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0008] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 7, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 7, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 19, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 19; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 25, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 25, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 7, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 7, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 7, and (iv ... CDR2 of amino acid sequence 31, or with SEQ ID NO:The TL1A binding protein comprises (iii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 37, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 37. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence of SEQ ID NO: 7, (ii) a CDR2 having an amino acid sequence of SEQ ID NO: 13, and (iii) a CDR3 having an amino acid sequence of SEQ ID NO: 19; and a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence of SEQ ID NO: 25, (ii) a CDR2 having an amino acid sequence of SEQ ID NO: 31, and (iii) a CDR3 having an amino acid sequence of SEQ ID NO: 37. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

[0009] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 8, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 8, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 20, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 20; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 26, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 26, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 8, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 8, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 8, and (iv ... one or two amino acid substitutions compared to the sequence of SEQ ID NO: 8; and (viii) a CDR2 having the amino acid sequence according to SEQ ID NO: 8, and (viii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 8; and (viii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 8, and (viii) a CDR2 having one or two amino acid substitutions compared to the sequence of CDR2 of the amino acid sequence of SEQ ID NO: 32, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, page 3 / 179, 26 CN 121843714 A, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 38, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, page 26 ...The sequence 38 has a CDR3 with one or two amino acid substitutions. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 8, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 20; and a light chain variable region (VL), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 26, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 32, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 38. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

[0010] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 1, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 1, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 21, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 31, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 11, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 11, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (viii) a CDR3 having the amino acid sequence according to SEQ ID NO: 11, and (viii ...2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (viii) a C The CDR2 of the amino acid sequence of SEQ ID NO: 41, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 51, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 51, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 51. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 1, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 1, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 51.The TL1A binding protein comprises (i) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 21; and (b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 31, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 41, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 51. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0011] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 2, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 2, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 22, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22; and a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 32, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 22, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 22, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22, and (viii) a CDR2 having the amino acid sequence according to SEQ ID NO: 22, and (viii) a CDR2 having the amino acid sequence according to SEQ ID NO: 22, and (viii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22; and (viii) a CDR2 having the amino acid sequence according to SEQ ID NO: 22, and (viii) a CDR2 having one or two amino acid substitutions compared to the sequence of ... The CDR2 of the amino acid sequence of SEQ ID NO: 42, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 42, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 52, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 52. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) a CDR1 having the amino acid sequence of SEQ ID NO: 2, (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 12, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 22; and b) a light chain variable region (VL), which is described on page 27 of specification 4 / 179.CN 121843714 A comprises (i) CDR1 having the amino acid sequence according to SEQ ID NO: 32, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 42, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 52. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0012] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 23, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 33, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 33, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 33, or (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33, and (viii) a CDR2 having the amino acid sequence according to SEQ ID NO: 33, and (viii) a CDR2 having one or two amino acid substitutions compared to the sequence of ... The CDR2 of the amino acid sequence according to SEQ ID NO: 43, or the CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 43, and (iii) the CDR3 having the amino acid sequence according to SEQ ID NO: 53, or the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 53. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 23; and b) a light chain variable region (VL), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 33, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 43, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 53.CDR3 of amino acid sequence NO: 53. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0013] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 24, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 24; and a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 34, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 34, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 4, and (iv) a CDR3 having the amino acid sequence according to SEQ ID NO: 4, and (viii) a CDR2 having the amino acid sequence according to SEQ ID NO: 4, and (viii ...2 having the amino acid sequence according to SEQ ID NO: 4, and (v (iii) CDR2 of the amino acid sequence of SEQ ID NO: 44, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 44, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 54, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 54. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 4, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 14, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 24; and b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 34, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 44, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 54. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications.L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

[0014] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), as described on page 5 / 179 of CN 121843714 A. The heavy chain variable region comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 321, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 321, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 430, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 539, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 539; and a light chain variable region (VL), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 648, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 639. The sequence of 648 is compared to CDR1 having one or two amino acid substitutions, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 757, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 757, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 866, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 866. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 321, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 430, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 539; and b) a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 648, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 757, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 866. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0015] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 341, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 341, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 450, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 559, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 559; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 668, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 668, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 341, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 450, and (iv) a CDR3 having the amino acid sequence according to SEQ ID NO: 450, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iv) a CDR3 having the amino acid sequence according to SEQ ID NO: 559, and (iv) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 559; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 668, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 668, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 660, (iv (iii) CDR2 having the amino acid sequence of SEQ ID NO: 777, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 777, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 886, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 886. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 341, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 450, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 559; and b) a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 668, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 777, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 886. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0016] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) having according to SEQ ID NO:(ii) a CDR1 having the amino acid sequence of SEQ ID NO: 345, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 454, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 563, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 563; and (b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence of SEQ ID NO: 672, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 672, and (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 781, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 781, and (iii) a CDR2 having the amino acid sequence of SEQ ID NO: 781, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 781; and (iv) a CDR2 having the amino acid sequence of SEQ ID NO: 781, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 781; and (viii) a CDR2 having the amino acid sequence of SEQ ID NO: 781, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 781; and (iv) a CDR2 having the amino acid sequence of SEQ ID NO: 781; and (viii) a CDR2 having the amino acid sequence of SEQ ID NO: 781; and (iviii) a CDR2 having the amino acid sequence of SEQ ID NO: 781; and (v ... The sequence of 781 is compared to CDR2 with one or two amino acid substitutions, and (iii) has CDR3 with the amino acid sequence according to SEQ ID NO: 890, or has CDR3 with one or two amino acid substitutions compared to the sequence of SEQ ID NO: 890. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 with the amino acid sequence according to SEQ ID NO: 345, (ii) CDR2 with the amino acid sequence according to SEQ ID NO: 454, and (iii) CDR3 with the amino acid sequence according to SEQ ID NO: 563; and b) a light chain variable region (VL), which comprises (i) CDR1 with the amino acid sequence according to SEQ ID NO: 672, (ii) CDR2 with the amino acid sequence according to SEQ ID NO: 781, and (iii) CDR3 with the amino acid sequence according to SEQ ID NO: 890. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0017] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 349, or with SEQ ID NO:The sequence comprises (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 458, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 458, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 567; and (b) a light chain variable region (VL) comprising (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 676, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 676, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 785, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 785, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 567; and (iii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 676; and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 785. The CDR3 of the amino acid sequence SEQ ID NO: 894, or the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 894. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 349, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 458, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 567; and b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 676, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 785, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 894. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0018] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 351, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 351, and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 460, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 351, and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 460, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 351, and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 351, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 351, and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 351, and (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of ...The CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 569, and (iii) the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 569; and b) a light chain variable region (VL) comprising (i) the CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 678, or the CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 678, (ii) the CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 787, or the CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 787, and (iii) the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 896. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which includes (i) CDR1 having the amino acid sequence according to SEQ ID NO: 351, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 460, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 569; and b) a light chain variable region (VL), which includes (i) CDR1 having the amino acid sequence according to SEQ ID NO: 678, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 787, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 896. In some embodiments, the TL1A-binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0019] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 354, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 354, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 463, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 463, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 463.The CDR3 of the amino acid sequence of SEQ ID NO: 572, or the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 572; and b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 681, or the CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 681, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 790, or the CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 790, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 899, or the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 899. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) comprising (i) CDR1 having an amino acid sequence according to SEQ ID NO: 354, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 463, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 572; and b) a light chain variable region (VL) comprising (i) CDR1 having an amino acid sequence according to SEQ ID NO: 681, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 790, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 899. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0020] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 365, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 365, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 474, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 474, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 583, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 583; and a light chain variable region (VL), the light chain variable region comprising (i) having(ii) CDR1 having the amino acid sequence according to SEQ ID NO: 692, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 692; (iii) CDR2 having the amino acid sequence according to SEQ ID NO: 801, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 801; and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 910, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 910. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) comprising (i) CDR1 having an amino acid sequence according to SEQ ID NO: 365, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 474, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 583; and b) a light chain variable region (VL) comprising (i) CDR1 having an amino acid sequence according to SEQ ID NO: 692, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 801, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 910. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, on page 8 / 179 of CN 121843714 A, the Fc domain contains amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

[0021] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 371, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 371, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 480, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 480, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 589, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 589; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 698, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 698, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 698, and ...The sequence of 698 is compared to CDR1 having one or two amino acid substitutions, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 807, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 807, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 916, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 916. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 371, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 480, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 589; and b) a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 698, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 807, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 916. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0022] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 372, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 372, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 481, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 481, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 590, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 590; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 691, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 691, (ii) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 691, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 691, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 691, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 691, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 691, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of ... CDR2 having the amino acid sequence according to SEQ ID NO: 808, or the amino acid sequence according to SEQ ID NO:The sequence of 808 is compared to CDR2 with one or two amino acid substitutions, and (iii) CDR3 with the amino acid sequence according to SEQ ID NO: 917, or CDR3 with one or two amino acid substitutions compared to the sequence of SEQ ID NO: 917. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 with the amino acid sequence according to SEQ ID NO: 372, (ii) CDR2 with the amino acid sequence according to SEQ ID NO: 481, and (iii) CDR3 with the amino acid sequence according to SEQ ID NO: 590; and b) a light chain variable region (VL), which comprises (i) CDR1 with the amino acid sequence according to SEQ ID NO: 691, (ii) CDR2 with the amino acid sequence according to SEQ ID NO: 808, and (iii) CDR3 with the amino acid sequence according to SEQ ID NO: 917. In some embodiments, the TL1A binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0023] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 373, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 373, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 482, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 482, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 591, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 591; and a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 700, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 700; and a CDR1 having the amino acid sequence according to SEQ ID NO: 700; a CDR1 having the amino acid sequence according to SEQ ID NO: 700; a CDR1 having the amino acid sequence according to SEQ ID NO: 700; a CDR1 having one or two amino acid substitutions compared to the sequence of ... The sequence of SEQ ID NO: 700 is compared to CDR1 having one or two amino acid substitutions, (ii) having CDR2 having the amino acid sequence according to SEQ ID NO: 809, or having CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) having the amino acid sequence according to SEQ ID NO:The CDR3 of the amino acid sequence of SEQ ID NO: 918, or the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 373, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 482, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 591; and b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 700, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 809, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 918. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

[0024] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 388, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 388, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 497, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 497, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 606, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 606; and a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 715, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 715, (ii) ... (iii) A CDR2 having the amino acid sequence according to SEQ ID NO: 824, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 824, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 933, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 933. In some embodiments, the TL1A binding protein comprises a)The heavy chain variable region (VH) comprises (i) CDR1 having the amino acid sequence according to SEQ ID NO: 388, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 497, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 606; and (b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 715, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 824, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 933. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0025] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 394, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 394, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 503, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 503, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 612, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 612; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 721, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721, (ii) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721, and (iii) a CDR1 having the amino acid sequence according to SEQ ID NO: 721, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721, and (ii) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721, and (iii) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721, and (iii) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721, and (iv ... The TL1A binding protein comprises (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 830, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 830, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 939, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 939. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR2 having the amino acid sequence according to SEQ ID NO: 830, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 939.(ii) a CDR1 having the amino acid sequence of SEQ ID NO: 503, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 612; and (b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence of SEQ ID NO: 721, (ii) a CDR2 having the amino acid sequence of SEQ ID NO: 830, and (iii) a CDR3 having the amino acid sequence of SEQ ID NO: 939. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0026] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 400, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 400, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 509, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 509, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 618, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 618; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 727, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 727, (ii) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 727, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 727, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 727, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 727, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 727, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of ... The CDR2 has the amino acid sequence according to SEQ ID NO: 836, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 836, and (iii) a CDR3 has the amino acid sequence according to SEQ ID NO: 945, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 945. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 400, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 509, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 945.CDR3 having an amino acid sequence of 618; and b) a light chain variable region (VL) comprising (i) CDR1 having an amino acid sequence according to SEQ ID NO: 727, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 836, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 945. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0027] Aspects of this disclosure relate to TL1A binding antibodies that specifically bind to an epitope on a TL1A polypeptide recognized by the antibody disclosed herein. This disclosure relates to TL1A-binding antibodies that specifically bind to epitopes on the TL1A polypeptide that are recognized by antibodies 1, 2, 3, 4, 6, 8, 10, 47, 49, 63, or 69 disclosed herein.

[0028] This disclosure relates to TL1A binding antibodies that specifically bind to a TL1A polypeptide comprising SEQ ID NO: 2493 at any of the following amino acid residues: Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 231, Asp 232, Ile 233, Ser 234, Tyr 238, Thr 239, Lys 240 and Lys 243. In some embodiments, the TL1A binding antibody specifically binds to the TL1A sequence at ten or more amino acid residues selected from the following: Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 231, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240, and Lys 243.

[0029] This disclosure relates to TL1A binding antibodies that specifically bind to a TL1A polypeptide comprising SEQ ID NO: 2493 at any of the following amino acid residues: Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tyr 238, and Thr 239. In some embodiments, the TL1A binding antibody specifically binds to the TL1A sequence at the following amino acid residues: Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tyr 238, and Thr 239.

[0030] This disclosure relates to a TL1A binding protein comprising: a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 3-8, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 3-8, (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NO: 9-14, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 9-14, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 15-20, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 15-20; and b) a light chain variable region (VL), the light chain variable region comprising (i) a heavy chain variable region having an amino acid sequence according to SEQ ID NO: 3-8, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 3-8; and (iii) a heavy chain variable region having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 3-8; and (iv ... (ii) CDR1 having an amino acid sequence according to any one of SEQ ID NO: 21-26, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 21-26, and (ii) CDR2 having an amino acid sequence according to any one of SEQ ID NO: 27-32, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 27-32, and(iii) A CDR3 having an amino acid sequence according to any one of SEQ ID NO: 33-38, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 33-38.

[0031] In some embodiments, the TL1A binding protein comprises VH and VL, wherein the VH comprises a sequence having at least 80% sequence identity with an amino acid sequence of any one of SEQ ID NO: 111-116, and the VL comprises a sequence having at least 80% sequence identity with an amino acid sequence of any one of SEQ ID NO: 117-122.

[0032] In some embodiments, the VH comprises a sequence having at least 80% sequence identity with an amino acid sequence of SEQ ID NO: 111, and the VL comprises a sequence having at least 80% sequence identity with an amino acid sequence of SEQ ID NO: 117.

[0033] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 112, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 118.

[0034] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 113, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 119.

[0035] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 114, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 120.

[0036] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 115, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 121.

[0037] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 116, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 122.

[0038] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 3, and (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 9.(ii) CDR2 of the sequence according to SEQ ID NO: 9, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 9, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 15, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 15; and (iv) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 21, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 27, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 27, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 33, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 9, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 33, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 9, and (iv) CDR2 ...33, and (iv) CDR2 having one or two amino acid substitutions compared to the sequence The sequence 33 has a CDR3 with one or two amino acid substitutions. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 9, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 15; and b) a light chain variable region (VL), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 21, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 27, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 33. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0039] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 10, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 10, and (iii ...The CDR3 of the amino acid sequence of SEQ ID NO: 16, or the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 16; and b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 22, or the CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 28, or the CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 28, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 34, or the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 34. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 4, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 10, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 16; and b) a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 22, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 28, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 34. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0040] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 5, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 5, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 17, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 17; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 5, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 5; and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 5, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 5; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 5, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 5; and (iii) a CDR1 having the amino acid sequence according to SEQ ID NO: 5, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 5; and (iv) a heavy chain variable region having the amino acid sequence according to SEQ ID NO: 5, or a CDR1 ...(ii) CDR1 of the amino acid sequence of SEQ ID NO: 23, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23, and (iii) CDR2 of the amino acid sequence of SEQ ID NO: 29, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 29, and (iii) CDR3 of the amino acid sequence of SEQ ID NO: 35, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 35. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having the amino acid sequence according to SEQ ID NO: 5, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 11, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 17; and b) a light chain variable region (VL), which comprises (i) CDR1 having the amino acid sequence according to SEQ ID NO: 23, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 29, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 35. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

[0041] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 6, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 6, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 18, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 18; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 24, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 24, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 6, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 6, and (iv) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, and (viii) a CDR2 having the amino acid sequence according to SEQ ID NO: 18 ...(iii) CDR2 of the amino acid sequence of SEQ ID NO: 30, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 30, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 36, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 36. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 6, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 12, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 18; and b) a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 24, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 30, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 36. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0042] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 7, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 7, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 19, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 19; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 25, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 25, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 7, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 7, and (iv) a CDR2 having the amino acid sequence according to SEQ ID NO: 7, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of ... (iii) CDR2 of the amino acid sequence of SEQ ID NO: 31, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 37, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31.The sequence NO: 37 has a CDR3 with one or two amino acid substitutions. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 7, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 19; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 25, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 31, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 37. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications, as described on page 14 / 179 of the specification, 37 CN 121843714 A L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

[0043] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 8, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 8, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 20, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 20; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 26, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 26, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 8, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 8, and (iv) a CDR2 having the amino acid sequence according to SEQ ID NO: 8, and (viii ... The CDR2 of the amino acid sequence SEQ ID NO: 32, or the CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, and (iii) the CDR3 having the amino acid sequence according to SEQ ID NO: 38, or the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 38. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i)The TL1A binding protein comprises (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 8, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 20; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 26, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 32, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 38. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE). In some embodiments, the TL1A binding protein or the TL1A binding antibody binds TL1A at a KD of less than about 0.5 nanomolar (nM).

[0044] This document describes a TL1A binding protein comprising a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 3-8, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 3-8; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NO: 9-14, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 9-14; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 15-20, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 15-20.

[0045] This document describes a TL1A binding protein comprising a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 21-26, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 21-26; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NO: 27-32, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 27-32; and (iii) a CDR2 having an amino acid sequence according to SEQ ID NO: 27-32.CDR3 of any one of the amino acid sequences in SEQ ID NO: 33-38, or CDR3 having one or two amino acid substitutions compared to any one of SEQ ID NO: 33-38.

[0046] This document describes a method for obtaining an antibody that specifically binds to certain epitope portions of the TL1A sequence comprising SEQ ID NO: 2493, wherein the method comprises assessing whether the antibody specifically binds to the certain epitope portions, and isolating or selecting the antibody that binds to the certain epitope portions, wherein the certain epitope portions have the amino acid residues Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 227, Tyr 231, and Thr 232 of SEQ ID NO: 2493. Specification 15 / 179 pages 38 CN 121843714 A

[0047] In addition, this document describes TL1A binding proteins that specifically bind to TL1A peptides comprising SEQ ID NO: 2493 or 2494, wherein the TL1A binding protein is an antibody.

[0048] This document describes a TL1A binding protein comprising: a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 1-4 and 313-421, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 1-4 and 313-421, (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NO: 11-14 and 422-530, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 11-14 and 422-530, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 21-24 and 531-639, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 11-14 and 422-530, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 11-24 and 531-639, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 11-24 and 531-639, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 11-24 and 531-639, and (iv) ... CDR3 having one or two amino acid substitutions compared to any one of SEQ ID NO: 21-24 and 531-639; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 31-34 and 640-748, or having an amino acid sequence corresponding to any one of SEQ ID NO: 1-4 and 313-421.(ii) CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 41-44 and 749-857, or CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 41-44 and 749-857, and (iii) CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 51-54 and 858-966, or CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 51-54 and 858-966.

[0049] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of any one of SEQ ID NO: 181-184 and 2275-2383, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of any one of SEQ ID NO: 191-194 and 2384-2492.

[0050] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 181, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 191.

[0051] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 182, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 192.

[0052] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 183, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 193.

[0053] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 184, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 194.

[0054] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2283, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2392.

[0055] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2303, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2412.

[0056] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2307, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2416.

[0057] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2311, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2420.

[0058] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2313, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2422.

[0059] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2316, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2425. Specification 16 / 179 pages 39 CN 121843714 A

[0060] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2327, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2436.

[0061] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2333, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2442.

[0062] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2334, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2443.

[0063] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2335, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2444.

[0064] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2350, and VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2459.

[0065] In some embodiments, VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2335.The amino acid sequence of SEQ ID NO: 2356 has at least 80% sequence identity, and VL contains a sequence that has at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2465.

[0066] In some embodiments, VH contains a sequence that has at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2362, and VL contains a sequence that has at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2471.

[0067] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 1, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 1, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 21, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 31, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 11, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 11, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (viii) a CDR3 having the amino acid sequence according to SEQ ID NO: 11, and (viii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 11, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (viii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (viii (iii) CDR2 of the amino acid sequence of SEQ ID NO: 41, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 41, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 51, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 51. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 1, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 11, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 21; and b) a light chain variable region (VL), the light chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 31, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 41, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 51. In some embodimentsIn this example, the TL1A binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0068] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 2, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 2, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 22, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22; and a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 32, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 22, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 22, and (iv) a CDR2 having the amino acid sequence according to SEQ ID NO: 22, and (viii ... (iii) CDR2 having the amino acid sequence of SEQ ID NO: 42, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 42, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 52, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 52. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 2, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 12, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 22; and b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 32, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 42, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 52. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications.L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

[0069] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 23, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 33, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 33, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 33, or (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33, and (viii) a CDR2 having the amino acid sequence according to SEQ ID NO: 33, and (viii) a CDR2 having one or two amino acid substitutions compared to the sequence of ... (iii) CDR2 of the amino acid sequence of SEQ ID NO: 43, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 43, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 53, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 53. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH) comprising (i) CDR1 having an amino acid sequence according to SEQ ID NO: 3, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 13, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 23; and b) a light chain variable region (VL) comprising (i) CDR1 having an amino acid sequence according to SEQ ID NO: 33, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 43, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 53. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0070] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising(i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 4; (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 14; and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 24, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 24; and a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 34, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 34; (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 44, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 44; and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 4; The CDR3 of the amino acid sequence 54, or the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 54. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 24; and b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 34, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 44, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 54. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0071] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 321, or with SEQ ID NO:The sequence comprises (ii) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 430, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 539; and a light chain variable region (VL) comprising (i) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 648, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 648, (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 757, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 757, and (iii) a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 866, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 866, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 757, and (iii) a CDR3 ...2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 8 The sequence NO: 866 has a CDR3 with one or two amino acid substitutions. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 321, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 430, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 539; and b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 648, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 757, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 866. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0072] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 341, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 341, and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 450, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 341, and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 450, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 341, and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 341, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 341, and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 341, and (ii) a CDR2 having one or two amino acid substitutions compared to the sequence of ...The CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 559, and (iii) the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 559; and (b) a light chain variable region (VL) comprising (i) the CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 668, (ii) the CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 777, and (iii) the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 886. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 341, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 450, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 559; and b) a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 668, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 777, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 886. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0073] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), as described on page 42 of CN 121843714 A, wherein the heavy chain variable region comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 345, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 345, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 454, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 454, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO:The CDR3 of the amino acid sequence of SEQ ID NO: 563, or the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 563; and b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 672, or the CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 672, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 781, or the CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 781, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 890, or the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 890. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 345, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 454, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 563; and b) a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 672, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 781, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 890. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0074] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 349, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 349, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 458, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 458, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 567, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 567; and b) a light chain variable region (VL), the light chain variable region comprising (i)(ii) CDR1 having the amino acid sequence according to SEQ ID NO: 676, or CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 676; and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 785, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 785; and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 894, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 894. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 349, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 458, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 567; and b) a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 676, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 785, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 894. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0075] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 351, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 351, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 460, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 460, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 569, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 569; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 678, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 460; and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 460, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 460; and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 569; and (iv) a light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 678, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 460; and (iv) a CDR2 having the amino acid sequence according to SEQ ID NO: 460; and (iv) ... NO:The sequence of 678 is compared to CDR1 having one or two amino acid substitutions, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 787, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 787, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 896, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 896. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 351, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 460, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 569; and b) a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 678, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 787, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 896. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0076] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 354, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 354, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 463, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 463, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 572, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 572; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 681, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 681, (ii) ... CDR2 having the amino acid sequence according to SEQ ID NO: 790, or the same as SEQ ID NO:The CDR2 has one or two amino acid substitutions compared to the sequence of SEQ ID NO: 790, and the CDR3 has one or two amino acid substitutions compared to the sequence of SEQ ID NO: 899. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 354, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 463, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 572; and b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 681, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 790, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 899. In some embodiments, the TL1A binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0077] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 365, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 365, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 474, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 474, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 583, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 583; and a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 692, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 692, (ii) ... (iii) A CDR2 having the amino acid sequence according to SEQ ID NO: 801, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 801, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 910, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 801.The sequence of 910 has a CDR3 with one or two amino acid substitutions. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 365, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 474, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 583; and b) a light chain variable region (VL), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 692, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 801, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 910. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

[0078] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 371, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 371, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 480, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 480, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 589, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 589; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 698, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 698, (ii) ... (iii) A CDR2 having the amino acid sequence according to SEQ ID NO: 807, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 807, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 916, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 916. In some embodiments, the TL1A binding protein comprises a)The heavy chain variable region (VH) comprises (i) CDR1 having the amino acid sequence according to SEQ ID NO: 371, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 480, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 589; and (b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 698, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 807, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 916. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0079] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 372, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 372, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 481, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 481, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 590, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 590; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 691, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 691, (ii) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 691, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 691, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 691, and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 372, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 372, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 590, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 590, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 691, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 691, and (iv) a The TL1A binding protein comprises (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 808, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 808, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 917, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 917. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 372, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 481.(iii) a CDR2 having an amino acid sequence according to SEQ ID NO: 590; and (b) a light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 691, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 808, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 917. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, as described on page 45 of CN 121843714 A of specification 22 / 179, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0080] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 373, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 373, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 482, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 482, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 591, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 591; and a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 700, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 700, (ii) ... The CDR2 has the amino acid sequence according to SEQ ID NO: 809, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) a CDR3 has the amino acid sequence according to SEQ ID NO: 918, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 373, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 482, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 591; and b)The light chain variable region (VL) comprises (i) CDR1 having the amino acid sequence according to SEQ ID NO: 700, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 809, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 918. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0081] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 388, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 388, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 497, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 497, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 606, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 606; and a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 715, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 715, (ii) ... The TL1A binding protein comprises (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 824, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 824, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 933, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 933. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 388, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 497, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 606; and b) a light chain variable region (VL), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 715, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 824, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 824, (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 824, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 933.(iii) CDR2 having the amino acid sequence of SEQ ID NO: 933, and (iii) CDR3 having the amino acid sequence of SEQ ID NO: 933. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0082] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 394, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 394, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 503, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 503, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 612, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 612; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 721, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721; and (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 721, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721; and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 721; and (iv) a CDR1 ... one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721; and (iv) a CDR1 having the amino acid sequence according to SEQ ID NO: 721; and (iv) a CDR1 having the amino acid sequence according to SEQ ID NO: 721; and (iv) a CDR (ii) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 830, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 830, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 939, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 939. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 394, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 503, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 612; and b) a light chain variable region (VL), the light chain variable region comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 721, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 830, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 939.The amino acid sequence of CDR3. In some embodiments, the TL1A binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0083] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 400, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 400, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 509, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 509, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 618, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 618; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 727, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 727, (ii) a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 727, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 727, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 727, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 727, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 727, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of ... (iii) A CDR2 having the amino acid sequence according to SEQ ID NO: 836, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 836, and (iii) A CDR3 having the amino acid sequence according to SEQ ID NO: 945, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 945. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 400, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 509, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 618; and b) a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 727, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 836, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 945. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain.In the example, the Fc domain contains amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

[0084] This document describes a TL1A binding protein comprising a heavy chain variable region (VH), the heavy chain variable region comprising: (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 1-4 and 313-421, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 1-4 and 313-421; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NO: 11-14 and 422-530, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 11-14 and 422-530; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 21-24 and 531-639, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 11-14 and 422-530; and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 11-24 and 531-639, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 11-24 and 531-639; and (iv) a CDR2 ... CDR3 is an amino acid sequence with one or two amino acid substitutions compared to any one of 21-24 and 531-639.

[0085] This document describes a TL1A binding protein comprising a light chain variable region (VL), wherein the light chain variable region comprises: (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 31-34 and 640-748, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 1-4 and 313-421; (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NO: 41-44 and 749-857, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 41-44 and 749-857; and (iii) a CDR2 having an amino acid sequence according to SEQ ID NO: CDR3 having an amino acid sequence of any one of SEQ ID NO: 51-54 and 858-966, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 51-54 and 858-966.

[0086] An aspect of this disclosure relates to a composition comprising the TL1A binding protein described herein and a pharmaceutically acceptable carrier. An aspect of this disclosure relates to an injectable liquid composition comprising the TL1A binding protein described herein and a pharmaceutically acceptable carrier.

[0087] This disclosure relates to an isolated nucleic acid that encodes the TL1A binding protein described herein.

[0088] This disclosure relates to a recombinant host cell that comprises the isolated nucleic acid.

[0089] This document describes a method for producing a TL1A binding protein that specifically binds to a TL1A polypeptide comprising SEQ ID NO: 2493 or 2494, wherein the TL1A antigen-binding protein is an antibody.

[0090] This disclosure relates to a method for obtaining an antibody that specifically binds to certain epitope portions of the TL1A sequence comprising SEQ ID NO: 2493, wherein the method includes assessing whether the antibody specifically binds to the certain epitope portions, and isolating or selecting antibodies that bind to the certain epitope portions, wherein the certain epitope portions have ten or more amino acid residues selected from the following: Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tyr 238, and Thr 239.

[0091] An aspect of this disclosure relates to a method for obtaining an antibody that specifically binds to certain epitope portions of a TL1A sequence comprising SEQ ID NO: 2493, wherein the method includes assessing whether the antibody specifically binds to the certain epitope portions, and isolating or selecting the antibody that binds to the certain epitope portions, wherein the certain epitope portions have the amino acid residues Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tyr 238, and Thr 239 of SEQ ID NO: 2493.

[0092] This disclosure relates to a method for producing a TL1A binding protein that specifically binds to a TL1A polypeptide comprising SEQ ID NO: 2493 at any of the amino acid residues in Table 12, 13, or 14, wherein the TL1A antigen-binding protein is an antibody. In some embodiments, the TL1A binding antibody binds to the TL1A polypeptide comprising SEQ ID NO: 2493 at any of the following amino acid residues.The TL1A peptide comprising SEQ ID NO: 2493 specifically binds to the following amino acid residues: Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Gln104, and Arg103. In some embodiments, the TL1A binding antibody specifically binds to the TL1A peptide comprising SEQ ID NO: 2493 at any of the following amino acid residues: Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123, and Arg 156.

[0093] This disclosure relates to a method for obtaining an antibody that specifically binds to certain epitope portions of a TL1A sequence comprising SEQ ID NO: 2493 or SEQ ID NO: 2494, wherein the method comprises: assessing whether the antibody specifically binds to the certain epitope portions, and isolating or selecting antibodies that bind to the certain epitope portions, wherein the certain epitope portions are recognized by the antibodies described herein; or having amino acid residues Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123, and Arg 156 of SEQ ID NO: 2493, or having SEQ ID NO: The amino acid residues of 2493 are Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Gln104, and Arg103.

[0094] An aspect of this disclosure relates to a method for obtaining an antibody that specifically binds to certain epitope portions of TL1A, said method being performed by competitively inhibiting the binding of antibodies disclosed herein (e.g., antibodies 1, 2, 3, 4, 6, 8, 10, 47, 49, 63, or 69 disclosed herein).

[0095] An aspect of this disclosure relates to a method for treating inflammatory gastrointestinal diseases in patients in need, said method comprising administering an effective amount of the TL1A binding protein described herein subcutaneously or intravenously to said patient. In some embodiments, the administration of the TL1A binding protein is subcutaneous. In some embodiments, the administration of the TL1A binding protein is intravenous. In some embodiments, the method includes administering TL1A binding protein to a patient two or more times at intervals of about 2 weeks to about 12 weeks or longer.

[0096] An aspect of this disclosure relates to a method of treating inflammatory bowel disease in a patient in need, the method comprising administering an effective amount of the TL1A binding protein described herein subcutaneously or intravenously to the patient. In some embodiments, the inflammatory bowel disease is Crohn's disease or ulcerative colitis. In some embodiments, the administration of the TL1A binding protein is subcutaneous. In some...In some embodiments, the administration of TL1A binding protein is intravenous. In some embodiments, the method includes administering TL1A binding protein to a patient two or more times at intervals of about 2 weeks to about 12 weeks or longer.

[0097] An aspect of this disclosure relates to a method of treating an inflammatory disease in a patient in need, the method comprising administering an effective amount of the TL1A binding protein described herein subcutaneously or intravenously to the patient. In some embodiments, the inflammatory disease is psoriasis, psoriatic arthritis, or hidradenitis suppurativa.

[0098] In some embodiments, the administration of TL1A binding protein is subcutaneous. In some embodiments, the administration of TL1A binding protein is intravenous. In some embodiments, the method includes administering TL1A binding protein to a patient two or more times at intervals of about 2 weeks to about 12 weeks or longer. Brief Description of the Drawings

[0099] Figure 1 is a diagram depicting the TL1A binding antibody (antibody 10) described herein and various comparative antibodies binding membrane TL1A. Comparative antibody 1 has a substantially identical amino acid sequence to RVT-3101 and is referred to herein as RVT-3101; comparative antibody 2 has a substantially identical amino acid sequence to MK-7240 and is referred to herein as MK-7240; comparative antibody 3 has a substantially identical amino acid sequence to TEV-48574 and is referred to herein as TEV-48574.

[0100] Figures 2A-2B depict the binding of TL1A monomers and TL1A trimers of various comparative antibodies compared to the TL1A binding antibodies disclosed herein.

[0101] Figures 3A-3D depict the inhibition of apoptosis of various comparative antibodies compared to the TL1A binding antibodies disclosed herein.

[0102] Figures 4A-4E depict the half-life of the TL1A binding antibodies disclosed herein in non-human primates. Figure 4F depicts the half-life of the TL1A binding antibodies disclosed herein in Tg276 mice expressing human FcRn.

[0103] Figures 5A and 5B depict the inhibition of TL1A-induced apoptosis in response to various comparative antibodies and the TL1A-binding antibody described herein.

[0104] Figures 6A-6C depict formulation data of the TL1A-binding antibody described herein compared to various comparative antibodies.

[0105] Figures 7A-7F depict chemical and pharmacokinetic data of the TL1A-binding antibody described herein compared to various comparative antibodies.

[0106] Figure 8A depicts a cryo-electron micrograph of the epitopes of the comparative TL1A-binding antibody. Figure 8B depicts a cryo-electron micrograph of the epitopes of TL1A-binding antibody 10 (Page 26 / 179, CN 121843714 A). Detailed Description

[0107] It should be understood that the foregoing general description and the following detailed description are exemplary and illustrative only and are not intended to limit this disclosure.

[0108] The section headings used herein are for typographical purposes only and should not be construed as limiting the subject matter.

[0109] All documents or portions thereof cited in this application, including but not limited to patents, patent applications, articles, books and monographs, are hereby expressly incorporated in their entirety by reference for any purpose. Definitions

[0110] Unless otherwise indicated, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. Unless otherwise indicated or apparent from the context, the following terms have the following meanings:

[0111] As used herein, unless otherwise indicated, the term “antibody” should be understood to mean an intact antibody (e.g., an intact monoclonal antibody), or a fragment thereof (such as an Fc fragment of an antibody (e.g., an Fc fragment of a monoclonal antibody)), or an antigen-binding fragment of an antibody (e.g., an antigen-binding fragment of a monoclonal antibody), including modified, engineered or chemically conjugated intact antibodies, antigen-binding fragments, or Fc fragments. Typically, an antibody is a polyprotein containing four polypeptide chains. The two polypeptide chains are called immunoglobulin heavy chains (H chains) and two polypeptide chains are called immunoglobulin light chains (L chains). The immunoglobulin heavy and light chains are linked by interchain disulfide bonds. The light chain consists of one variable region (VL) and one constant region (CL). The heavy chain consists of one variable region (VH) and at least three constant regions (CH1, CH2, and CH3). The variable region determines the antibody binding specificity. Each variable region contains three hypervariable regions (called complementarity-determining regions (CDRs)) flanked by four relatively conserved regions (called frame regions (FRs)). The scope of FR and CDR has been defined (Kabat et al. (1991) Sequences of Proteins of Immunological Interest, 5th ed., US Department of Health and Human Services, NIH Publication No. 91-3242; and Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917). Three CDRs (designated CDR1, CDR2, and CDR3) contribute to antibody binding specificity. Naturally occurring antibodies have been used as starting materials for engineered antibodies, such as chimeric and humanized antibodies. Examples of antibody-based antigen-binding fragments include Fab, Fab', (Fab')2, Fv, single-chain antibodies (e.g., scFv), microantibodies, and bispecific antibodies. Examples of modified or engineered antibodies include chimeric antibodies, humanized antibodies, and multispecific antibodies (e.g., bispecific antibodies).(body). An example of a chemically conjugated antibody is an antibody conjugated with a toxic moiety.

[0112] The terms “variable domain” and “variable region” are used interchangeably and refer to portions of an antibody or immunoglobulin domain that exhibit variability in their sequence and are involved in determining the specificity and binding affinity of a particular antibody. The variability is not uniformly distributed throughout the variable domain of an antibody; it is concentrated in subdomains of each heavy and light chain variable region. These subdomains are called “hypervariable regions” or “complementarity-determining regions” (CDRs). The more conserved (i.e., non-hypervariable) portions of the variable domain are called “framework” regions (FRMs or FRs) and provide a scaffold for the six CDRs in three-dimensional space to form an antigen-binding surface.

[0113] As used herein, the “Fc polypeptide” of a dimer Fc refers to one of two polypeptides that form the dimer Fc domain, namely a polypeptide containing the C-terminal constant region of the immunoglobulin heavy chain, which is capable of stable self-association. For example, the Fc polypeptide of the dimer IgG Fc contains constant IgG CH2 and IgG CH3 domain sequences. Fc may belong to the classes IgA, IgD, IgE, IgG, and IgM. These classes are also designated as α, δ, ε, γ, and µ, respectively. Several of these can be further subdivided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2.

[0114] The terms “Fc receptor” and “FcR” are used to describe receptors that bind to the Fc region of an antibody. For example, an FcR may be a naturally occurring human FcR. Typically, an FcR is an FcR (γ receptor) that binds to an IgG antibody and includes receptors of the subclasses FcγRI, FcγRII, and FcγRIIII (including allelic variants and alternative spliced ​​forms of these receptors). FcγRII receptors include FcγRIIA (“activating receptor”) and FcγRIIB (“inhibitory receptor”), which have similar amino acid sequences and differ primarily in their cytoplasmic domains. Other isotypes of immunoglobulins can also bind to certain FcRs (see, for example, Janeway et al., *Immuno Biology: the immune system in health and disease*, (Elsevier Science Ltd., New York) (4th ed., 1999)). The activating receptor FcγRIIA contains an activation motif (ITAM) based on the tyrosine residue of the immune receptor in its cytoplasmic domain. The inhibitory receptor FcγRIIB contains an inhibitory motif (ITIM) based on the tyrosine residue of the immune receptor in its cytoplasmic domain (see review in Daëron).Annu. Rev. Immunol. [Annals of Immunology] 15:203–234 (1997)). FcRs are reviewed in Ravetch and Kinet, Annu. Rev. Immunol. [Annals of Immunology] 9:457–92 (1991); Capel et al., Immunomethods [Immunomethods] 4:25–34 (1994); and de Haas et al., J. Lab. Clin. Med. [Journal of Laboratory and Clinical Medicine] 126:330–41 (1995). The term “FcR” in this article encompasses other FcRs, including those to be identified in the future. The terminology also includes neonatal receptor FcRn, which is responsible for transferring maternal IgG to the fetus (Guyer et al., J. Immunol. [Journal of Immunology] 117:587 (1976); and Kim et al., J. Immunol. [Journal of Immunology] 24:249 (1994)).

[0115] The terms “recipient,” “individual,” “subject,” “host,” and “patient” are used interchangeably herein and, in some embodiments, refer to any mammalian subject requiring diagnosis, treatment, or therapy, particularly a human. For therapeutic purposes, “mammal” means any animal classified as a mammal, including humans, livestock, and farm animals, as well as laboratory animals, zoo animals, racing animals, or pet animals, such as dogs, horses, cats, cattle, sheep, goats, pigs, mice, rats, rabbits, guinea pigs, monkeys, etc. In some embodiments, the mammal is a human. None of these terms require medical supervision.

[0116] As used herein, the term “effective amount” refers to an amount of compound (e.g., the compound disclosed herein) sufficient to achieve a beneficial or desired result. Effective amounts may be administered in one or more doses, applications, or dosages, and are not intended to be limited to a particular formulation or route of administration. As used herein, the term “treatment” includes any effect that improves a condition, disease, symptom, etc., or alleviates its symptoms, for example, by relieving, reducing, moderating, reducing, or eliminating.

[0117] As used herein, the term “pharmaceutical composition” refers to a combination of an active pharmaceutical agent with an inert or active carrier, such that the composition is particularly suitable for in vivo or in vitro diagnostic or therapeutic use.

[0118] As used herein, the term “pharmaceuticalally acceptable carrier” refers to any standard pharmaceutical carrier, such as phosphate-buffered saline solutions, water, emulsions (e.g., oil / water or water / oil emulsions), and various types of wetting agents. These compositions may also include stabilizers and preservatives. For examples of carriers, stabilizers, and adjuvants, see, for example, Martin, Remington's Pharmaceutical Sciences, 15th Edition, Mack.Publ. Co., Easton, Pennsylvania (1975).

[0119] Unless the context is inappropriate, as used herein, the term “a / an” means “one or more” and includes the plural.

[0120] As used herein, unless the context clearly indicates otherwise, all numerical values ​​or ranges of values ​​are included as integers that are within or cover such ranges, and as fractions of values ​​or integers that are within or cover such ranges. Thus, for example, references to the range of 90%–100% include 91%, 92%, 93%, 94%, 95%, 95%, 96%, 97%, etc., and as in specification 28 / 179 pages 51 CN 121843714 A 91.1%, 91.2%, 91.3%, 91.4%, 91.5%, etc., 92.1%, 92.2%, 92.3%, 92.4%, 92.5%, etc., and so on. In another instance, mentioning a range of 1-5,000 times includes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20 times, etc., and 1.1, 1.2, 1.3, 1.4, 1.5 times, etc., 2.1, 2.2, 2.3, 2.4, 2.5 times, etc., and so on.

[0121] As used herein, “about” a value means a range that includes the value, and the range is from 10% below the value to 10% above the value. “About” a range means 10% below the lower limit of the range and spans to 10% above the upper limit of the range.

[0122] “Identity percentage (%)” refers to the degree to which two sequences (nucleotides or amino acids) have the same residues at the same position in the alignment. For example, “the amino acid sequence is X% identical to SEQ ID NO: Y” means that the amino acid sequence is % identical to SEQ ID NO: Y, and states that X% of the residues in the amino acid sequence are identical to the residues in the sequence disclosed in SEQ ID NO: Y. Typically, such calculations are performed using computer programs. Exemplary programs for comparing and aligning sequence pairs include ALIGN (Myers and Miller, 1988), FASTA (Pearson and Lipman, 1988; Pearson, 1990), and vacancy BLAST (Altschul et al., 1997), BLASTP, BLASTN, or GCG (Devereux et al., 1984).

[0123] Throughout this specification, where a composition is described as having, including, or comprising a specific component, or where a process or method is described as having, including, or comprising a specific step, the presence of substantially the listed components is also contemplated.The components constitute or are composed of the compositions disclosed herein, and the existence of processes and methods according to this disclosure that are substantially composed or are composed of the listed processing steps is also considered.

[0124] Generally, unless otherwise stated, the specified percentages of the composition are by weight. Additionally, if a variable is not defined herein, its prior definition shall prevail. TL1A Binding Protein

[0125] This document provides compositions, systems, and methods comprising a TL1A binding protein. The TL1A binding protein described herein may bind to a TL1A monomer, a TL1A trimer, or both, may have a picomolar potency against a TL1A monomer, a TL1A trimer, or both, and may have an extended half-life (e.g., compared to known TL1A-targeting antibodies), or a combination thereof. In some embodiments, the TL1A binding protein described herein allows for subcutaneous administration. In some embodiments, the TL1A binding protein described herein allows for administration, for example, every 8 weeks or every 12 weeks or longer. The TL1A binding protein described herein may also have improved specificity. The TL1A binding protein described in this article is specific for monomeric TL1A and trimeric TL1A, but not for related TNF superfamily proteins such as TNF, FasL, TRAIL, or LIGHT.

[0126] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 9, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 9, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 15, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 15; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 21, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 9, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 9, and (iv ... (iii) a CDR2 having the amino acid sequence of SEQ ID NO: 27, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 33, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33. In some embodiments, the TL1A binding protein comprises a)The heavy chain variable region (VH) comprises (i) CDR1 having the amino acid sequence according to SEQ ID NO: 3, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 9, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 15; and (b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 21, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 27, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 33. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0127] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 10, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 10, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 16, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 16; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 22, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 4, and (iv) a CDR2 having the amino acid sequence according to SEQ ID NO: 4, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of ... The CDR2 of the amino acid sequence SEQ ID NO: 28, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 28, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 34, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 34. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 4, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 34.(iii) CDR2 having the amino acid sequence of SEQ ID NO: 10, and (iii) CDR3 having the amino acid sequence of SEQ ID NO: 16; and (b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence of SEQ ID NO: 22, (ii) CDR2 having the amino acid sequence of SEQ ID NO: 28, and (iii) CDR3 having the amino acid sequence of SEQ ID NO: 34. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0128] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 5, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 5, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 17, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 17; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 23, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 5, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 5, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 5, and (iv ... The CDR2 of the amino acid sequence SEQ ID NO: 29, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 29, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 35, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 35. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 5, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 17; and b) a light chain variable region (VL), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 29, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 17.(ii) CDR1 having the amino acid sequence of SEQ ID NO: 29, and (iii) CDR3 having the amino acid sequence of SEQ ID NO: 35. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0129] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), as described in specification 30 / 179 pages 53 CN 121843714 A. The heavy chain variable region comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 6, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 6, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 18, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 18; and b) a light chain variable region (VL), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 24, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 24; and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 24, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 24; and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 24, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 24; and (iv) a heavy chain variable region (VL). (ii) CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 30, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 30, and (iii) CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 36. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 6, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 18; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 24, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 30, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 18.CDR3 is a 36-amino acid sequence. In some embodiments, the TL1A binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0130] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 7, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 7, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 19, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 19; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 25, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 25, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 7, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 7, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 7, and (iv ... The CDR2 of the amino acid sequence of SEQ ID NO: 31, or the CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31, and (iii) the CDR3 having the amino acid sequence of SEQ ID NO: 37, or the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 37. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) the CDR1 having the amino acid sequence of SEQ ID NO: 7, (ii) the CDR2 having the amino acid sequence of SEQ ID NO: 13, and (iii) the CDR3 having the amino acid sequence of SEQ ID NO: 19; and a light chain variable region (VL), which comprises (i) the CDR1 having the amino acid sequence of SEQ ID NO: 25, (ii) the CDR2 having the amino acid sequence of SEQ ID NO: 31, and (iii) the CDR3 having the amino acid sequence of SEQ ID NO: 37. In some embodiments, the TL1A binding protein includes an immunoglobulin Fc domain. In some embodiments, the Fc domain includes amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0131] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 8, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 8, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 20, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 20; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 26, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 20; and (ii) a heavy chain variable region comprising (i) a heavy chain variable region having the amino acid sequence according to SEQ ID NO: 26, or a heavy chain variable region having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 20; and (iii) a heavy chain variable region comprising (i) a heavy chain variable region having the amino acid sequence according to SEQ ID NO: 26, or a heavy chain variable region having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 20, and (iii ... The sequence of SEQ ID NO: 32 is compared to CDR1 with one or two amino acid substitutions, (ii) has CDR2 with the amino acid sequence according to SEQ ID NO: 32, or has CDR2 with one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, and (iii) has CDR3 with the amino acid sequence according to SEQ ID NO: 38, or has CDR3 with one or two amino acid substitutions compared to the sequence of SEQ ID NO: 38. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 8, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 14, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 20; and a light chain variable region (VL), which comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 26, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 32, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 38. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0132] In some embodiments, the TL1A binding antibody binds to an epitope on the TL1A peptide that is recognized by the antibody disclosed herein.Heterogeneous binding. In some embodiments, the TL1A-binding antibody specifically binds to an epitope on the TL1A peptide that is recognized by antibodies 1, 2, 3, 4, 6, 8, 10, 47, 49, 63, or 69 disclosed herein.

[0133] In some embodiments, the TL1A binding antibody specifically binds to the TL1A polypeptide comprising SEQ ID NO: 2493 at any of the following amino acid residues: Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 231, Asp 232, Ile 233, Ser 234, Tyr 238, Thr 239, Lys 240, and Lys 243. In some embodiments, the TL1A binding antibody specifically binds to the TL1A sequence at ten or more amino acid residues selected from the following: Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 231, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240, and Lys 243 of SEQ ID NO: 2493. In some embodiments, the TL1A binding antibody specifically binds to the TL1A sequence at ten or more amino acid residues selected from the following: Arg103, Gln104, Ser234, Leu235, Val236, Asp237, Tyr238, Thr239, and Lys240 of SEQ ID NO: 2493. In some embodiments, the TL1A antigen-binding protein is an antibody.

[0134] In some embodiments, the TL1A binding protein specifically binds to an epitope of TL1A. In some embodiments, the TL1A binding protein specifically binds to the TL1A polypeptide comprising SEQ ID NO: 2493 at any of the following amino acid residues: Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tyr 238, and Thr 239. In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at the following amino acid residues: Arg103, Gln104, Ser234, Leu235, Val236, Asp237, Tyr238, Thr239, and Lys240.

[0135] In some embodiments, this document describes a TL1A binding protein that specifically binds to a TL1A polypeptide comprising SEQ ID NO: 2493 at any of the following amino acid residues: Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 15 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tye 238, and Trh 239, wherein the TL1A binding protein is an antibody. In some embodiments, the TL1A binding protein specifically binds to the TL1A sequence at the following amino acid residues: Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tye 238, and Thr (see specification 32 / 179 pages, 55 CN 121843714 A 239).

[0136] In some embodiments, the TL1A binding protein specifically binds to the TL1A sequence at at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or all 19 amino acid residues of the following: Val 102, Arg 103, Gln 104, Thr 105, Thr 107, Gln 108, His 118, Trp 119, Glu 120, Glu 122, Leu 123, Gly 124, Lys 137, Arg 156, Gly 157, Met 158, Ser 234, Tye 238 and Thr 239 of SEQ ID NO: 2493.

[0137] In some embodiments, the TL1A-binding protein is at least 10, 11, 12, 13, 14, 15, 16, 17, 18, 19,Specific binding to the TL1A sequence at amino acid residues 20, 21, 22, 23, 24, 25, 26, 27, and 28 of SEQ ID NO: 2493: Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, His 118, Trp 119, Glu 120, His 121, Glu 122, Leu 123, Gly 124, Tyr 134, Asn 136, Arg 156, Gly 157, Met 158, Thr 159, Ser 206, Asn 207, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239 and Lys 240.

[0138] In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at at least 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or all of the following amino acid residues: Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, Pro 115, Arg 156, Met 158, Thr 159, Ser 160, Glu 161, Ala 168, Gly 169, Arg 170, Pro 171, Lys 173, Asp 175, Gln 193, Ser 206, Asn 207, Ser 231, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240 and Lys 243.

[0139] In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 21, 22 or all of the following amino acid residues: Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Asn 112, Pro 115, Leu 117, Arg 156, Gly 157, Met 158, Thr 159, Ser 160, Glu 161, Arg 170, Lys 173, Asp 175, Ser 176, Val201, Ser 206, Asn 207, Trp 208, Phe 209, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240 and Lys 243.

[0140] In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 or all of the following amino acid residues: Val 101, Val 102, Arg 103, Gln 104, His 118, Trp 119, Glu 120, His 121, Glu 122, Leu 123, Gly 124, Tyr 134, Thr 135, Lys 137, Tyr 188, Glu 190, Pro 191, Thr 192, Gln 193, Thr 239, Lys 240, Glu 241 and Asp 272.

[0141] In some embodiments, the TL1A binding protein specifically binds to the TL1A sequence at at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or all of the following amino acid residues: Val 102, Arg 103, Gln 104, Pro 106, His 118, Glu 120, Glu 122, Leu 123, Gly 124, Asn 136, Arg 156, Gly 157, Ser 234, Tyr 238 and Thr 239 of SEQ ID NO: 2493.

[0142] In some embodiments, the TL1A binding protein specifically binds to the TL1A sequence at at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or all of the following amino acid residues: Val 101, Val 102, Arg 103, Gln 104, Thr 105, Gln 108, Glu 120, Glu 122, Leu 123, Arg 156, Gly 157, Met 158 ​​and Tyr 238 of SEQ ID NO: 2493.

[0143] In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or all of the following amino acid residues: Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, His of SEQ ID NO: 2493.118, Glu 120, Glu 122, Leu 123, Gly 124, Arg 156, Instruction manual 33 / 179 pages 56 CN 121843714 A Ser 234, Tyr 238 and Thr 239.

[0144] In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at at least 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or all of the following amino acid residues: Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, Leu 117, His 118, Trp 119, Arg 156, Gly 157, Lys 173, Met 196, Ser 206, Ser 231, Asp 106. 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240 and Lys 243.

[0145] In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at at least 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or all of the following amino acid residues: Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, Gln 113, Pro 115, Leu 117, His 118, Trp 119, Arg 156, Lys 173, Ser 206, Asn 207, Ser 231, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240, and Lys 243.

[0146] In some embodiments, the TL1A binding protein specifically binds to the TL1A sequence at at least 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, and 26 amino acid residues of SEQ ID NO: 2493, namely Val 101, Val 102, Arg 103, Gln 104, Thr.105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, Leu 117, His 118, Trp 119, Arg 156, Lys 173, Ser 231, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240 and Lys 243.

[0147] In some embodiments, the TL1A-binding protein specifically binds to the TL1A sequence at at least 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27 or all of the following amino acid residues: Thr 100, Val 101, Val 102, Arg 103, Gln 104, Thr 105, Pro 106, Thr 107, Gln 108, His 109, Phe 110, Lys 111, Gln 113, Pro 115, His 118, Trp 119, Glu 120, Arg 156, Asp 232, Ile 233, Ser 234, Leu 235, Val 236, Asp 237, Tyr 238, Thr 239, Lys 240, and Lys 243.

[0148] In some embodiments, the amino acid residues of the TL1A epitope bind to the complementary site of the antibody at a distance of 6 Å or less, 5 Å or less, 4 Å or less, 3 Å or less, or 2 Å or less.

[0149] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 1, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 1, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 21, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 31, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 11, and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 11, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (viii) a CDR3 having the amino acid sequence according to SEQ ID NO: 11, and (viii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 11, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (viii) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (viii(iii) CDR2 of the amino acid sequence of SEQ ID NO: 41, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 41, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 51, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 51. In some embodiments, the TL1A-binding protein comprises a) a heavy chain variable region (VH), which comprises (i) CDR1 having the amino acid sequence according to SEQ ID NO: 1, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 11, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 21; and b) a light chain variable region (VL), which comprises (i) CDR1 having the amino acid sequence according to SEQ ID NO: 31, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 41, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 51. In some embodiments, the TL1A-binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

[0150] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 2, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 2, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 22, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22; and a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 32, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, (ii) a CDR1 having the amino acid sequence according to SEQ ID NO: 22, (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 22, and (iv) a CDR2 having the amino acid sequence according to SEQ ID NO: 22, and (viii ... (iii) CDR2 of the amino acid sequence of SEQ ID NO: 42, or CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 42, and having according to SEQ IDCDR3 of the amino acid sequence of SEQ ID NO: 52, or CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 52. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 2, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 12, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 22; and b) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 32, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 42, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 52. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

[0151] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 23, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 33, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 33, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 33, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 33, and (iv) a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33, and (viii ... The CDR2 of the amino acid sequence of SEQ ID NO: 43, or the CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 53, and (iii) the CDR3 having the amino acid sequence according to SEQ ID NO: 53, or the CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 53. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i)The TL1A binding protein comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 23; and (b) a light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 33, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 43, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 53. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0152] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), as described in specification 35 / 179 pages 58 CN 121843714 A. The heavy chain variable region comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 24, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 24; and a light chain variable region (VL), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 34, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 34; and a light chain variable region (VL), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 34, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 34; and a light chain variable region (VL). The sequence of SEQ ID NO: 34 includes (ii) CDR1 having one or two amino acid substitutions compared to SEQ ID NO: 44, or CDR2 having one or two amino acid substitutions compared to SEQ ID NO: 44, and (iii) CDR3 having one or two amino acid substitutions compared to SEQ ID NO: 54. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH) comprising (i) CDR1 having the amino acid sequence of SEQ ID NO: 4, (ii) CDR2 having the amino acid sequence of SEQ ID NO: 14, and (iii) CDR2 having one or two amino acid substitutions compared to SEQ ID NO: 54.The TL1A binding protein comprises: (i) CDR3 having the amino acid sequence according to SEQ ID NO: 24; and (ii) a light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 34, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 44, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 54. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0153] This document describes a TL1A binding protein comprising a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 321, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 321, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 430, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 539, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 539; and a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 648, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 648, (ii) ... The TL1A binding protein comprises (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 757, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 757, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 866, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 866. In some embodiments, the TL1A binding protein comprises a) a heavy chain variable region (VH), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 321, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 430, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 539; and b) a light chain variable region (VL), which comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 757, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 757, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 866.(ii) CDR1 having the amino acid sequence of SEQ ID NO: 757, and (iii) CDR3 having the amino acid sequence of SEQ ID NO: 866. In some embodiments, the TL1A binding protein comprises an immunoglobulin Fc domain. In some embodiments, the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T, and T256E (YTE).

[0154] This document describes a TL1A binding protein, wherein the TL1A binding protein comprises a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 341, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 341, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 450, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 559, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 559; and b) a light chain variable region (VL), the light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 668, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 341; and (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 450, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450; and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 559; and (iv) a light chain variable region comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 668, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450; and (iii) a CDR2 having the amino acid sequence according to SEQ ID NO: 668, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450; and (iv) a CDR2 having the amino acid sequence according to SEQ ID NO: 450; and (iv) a CDR2 having the amino acid sequence according to SEQ ID NO: 45 (ii) CDR1 having one...

Claims

1. A TL1A-binding protein, wherein the TL1A-binding protein comprises: The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 9, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 9, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 15, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 15; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 21, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 27, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 27, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 33, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 10, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 10, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 16, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 16; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 22, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 28, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 28, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 34, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 34; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 5, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 5, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 17, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 17; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 23, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 29, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 29, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 35, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 35; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 6, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 6, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 18, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 18; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 24, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 24, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 30, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 30, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 36, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 36; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 7, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 7, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 19, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 19; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 25, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 25, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 31, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 37, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 37; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 8, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 8, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 20, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 20; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 26, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 26, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 32, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 38, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 38; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 1, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 1, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 21, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 31, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 41, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 41, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 51, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 51; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 2, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 2, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 22, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 32, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 42, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 42, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 52, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 52; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 23, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 33, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 43, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 43, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 53, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 53; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 24, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 24; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 34, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 34, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 44, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 44, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 54, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 54; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 321, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 321, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 430, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 539, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 539; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 648, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 648, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 757, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 757, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 866, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 866; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 341, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 341, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 450, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 559, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 559; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 668, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 668, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 777, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 777, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 886, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 886; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 345, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 345, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 454, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 454, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 563, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 563; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 672, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 672, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 781, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 781, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 890, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 890; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 349, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 349, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 458, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 458, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 567, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 567; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 676, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 676, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 785, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 785, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 894, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 894; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 351, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 351, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 460, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 460, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 569, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 569; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 678, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 678, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 787, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 787, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 896, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 896; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 354, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 354, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 463, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 463, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 572, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 572; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 681, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 681, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 790, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 790, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 899, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 899; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 365, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 365, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 474, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 474, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 583, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 583; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 692, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 692, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 801, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 801, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 910, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 910; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 371, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 371, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 480, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 480, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 589, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 589; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 698, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 698, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 807, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 807, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 916, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 916; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 372, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 372, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 481, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 481, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 590, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 590; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 691, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 691, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 808, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 808, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 917, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 917; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 373, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 373, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 482, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 482, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 591, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 591; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 700, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 700, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 809, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 918, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 388, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 388, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 497, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 497, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 606, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 606; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 715, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 715, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 824, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 824, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 933, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 933; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 394, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 394, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 503, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 503, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 612, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 612; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 721, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 830, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 830, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 939, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 939; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 400, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 400, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 509, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 509, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 618, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 618; as well as The light chain variable region (VL) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 727, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 727, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 836, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 836, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 945, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO:

945.

2. The TL1A-binding protein of claim 1, wherein the TL1A-binding protein comprises: The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 3, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 9, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 15; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 21, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 27, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 33; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 4, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 10, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO:

16. as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 22, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 28, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 34; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 5, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 11, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO:

17. as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 23, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 29, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 35; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 6, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 12, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO:

18. as well as The light chain variable region (VL) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 24, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 30, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 36; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 7, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 13, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 19; as well as The light chain variable region (VL) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 25, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 31, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 37; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 8, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 14, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 20; as well as The light chain variable region (VL) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 26, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 32, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 38; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 1, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 11, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO:

21. as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 31, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 41, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 51; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 2, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 12, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 22; as well as The light chain variable region (VL) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 32, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 42, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 52; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 3, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 13, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 23; as well as A light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 33, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 43, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 53; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 4, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 14, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 24; as well as The light chain variable region (VL) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 34, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 44, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 54; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 321, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 430, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 539; as well as A light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 648, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 757, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 866; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 341, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 450, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 559; as well as A light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 668, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 777, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 886; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 345, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 454, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 563; as well as A light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 672, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 781, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 890; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 349, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 458, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 567; as well as A light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 676, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 785, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 894; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 351, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 460, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO:

569. as well as A light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 678, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 787, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 896; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 354, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 463, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 572; as well as A light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 681, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 790, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 899; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 365, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 474, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 583; as well as A light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 692, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 801, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 910; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 371, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 480, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO:

589. as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 698, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 807, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 916; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 372, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 481, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 590; as well as A light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 691, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 808, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 917; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 373, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 482, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO:

591. as well as A light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to SEQ ID NO: 700, (ii) a CDR2 having an amino acid sequence according to SEQ ID NO: 809, and (iii) a CDR3 having an amino acid sequence according to SEQ ID NO: 918; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 388, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 497, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 606; as well as A light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 715, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 824, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 933; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 394, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 503, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 612; as well as A light chain variable region (VL) comprising (i) CDR1 having the amino acid sequence according to SEQ ID NO: 721, (ii) CDR2 having the amino acid sequence according to SEQ ID NO: 830, and (iii) CDR3 having the amino acid sequence according to SEQ ID NO: 939; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 400, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 509, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 618; as well as The light chain variable region (VL) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 727, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 836, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO:

945.

3. The TL1A binding protein of claim 1 or claim 2, wherein the TL1A binding protein comprises an immunoglobulin Fc domain.

4. A TL1A-binding protein, said TL1A-binding protein comprising: (a) a heavy chain variable region (VH), the heavy chain variable region comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 3-8, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 3-8, (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NO: 9-14, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 9-14, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 15-20, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 15-20; and (b) A light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 21-26, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 21-26, (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NO: 27-32, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 27-32, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 33-38, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 33-38.

5. The TL1A binding protein of claim 4, wherein the VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of any one of SEQ ID NO: 111-116, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of any one of SEQ ID NO: 117-122.

6. The TL1A binding protein as described in claim 4 or claim 5, wherein... The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 111, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO:

117. The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 112, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO:

118. The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 113, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO:

119. The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 114, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO:

120. The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 115, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 121, or The VH comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 116, and the VL comprises a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO:

122.

7. A TL1A-binding protein, wherein the TL1A-binding protein comprises: The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 9, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 9, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 15, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 15; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 21, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 27, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 27, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 33, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 10, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 10, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 16, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 16; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 22, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 28, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 28, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 34, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 34; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 5, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 5, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 17, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 17; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 23, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 29, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 29, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 35, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 35; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 6, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 6, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 18, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 18; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 24, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 24, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 30, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 30, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 36, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 36; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 7, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 7, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 19, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 19; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 25, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 25, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 31, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 37, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 37; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 8, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 8, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 20, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 20; as well as The light chain variable region (VL) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 26, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 26, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 32, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 38, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO:

38.

8. The TL1A-binding protein of claim 7, wherein the TL1A-binding protein comprises: The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 3, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 9, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 15; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 21, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 27, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 33; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 4, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 10, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO:

16. as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 22, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 28, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 34; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 5, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 11, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO:

17. as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 23, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 29, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 35; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 6, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 12, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO:

18. as well as The light chain variable region (VL) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 24, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 30, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 36; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 7, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 13, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 19; as well as The light chain variable region (VL) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 25, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 31, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 37; or The heavy chain variable region (VH) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 8, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 14, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO: 20; as well as The light chain variable region (VL) comprises (i) CDR1 having an amino acid sequence according to SEQ ID NO: 26, (ii) CDR2 having an amino acid sequence according to SEQ ID NO: 32, and (iii) CDR3 having an amino acid sequence according to SEQ ID NO:

38.

9. A TL1A-binding protein, said TL1A-binding protein comprising a heavy chain variable region (VH), said heavy chain variable region comprising: (i) A CDR1 having an amino acid sequence according to any one of SEQ ID NO: 3-8, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 3-8; (ii) A CDR2 having an amino acid sequence according to any one of SEQ ID NO: 9-14, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 9-14; and (iii) A CDR3 having an amino acid sequence according to any one of SEQ ID NO: 15-20, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 15-20.

10. A TL1A-binding protein, said TL1A-binding protein comprising a light chain variable region (VL), said light chain variable region comprising: (i) A CDR1 having an amino acid sequence according to any one of SEQ ID NO: 21-26, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 21-26; (ii) A CDR2 having an amino acid sequence according to any one of SEQ ID NO: 27-32, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 27-32; and (iii) A CDR3 having an amino acid sequence according to any one of SEQ ID NO: 33-38, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 33-38.

11. The TL1A binding protein according to any one of claims 1-8, wherein the TL1A binding protein is an antibody having an IgG1, IgG2 or IgG4 immunoglobulin Fc domain.

12. The TL1A binding protein of claim 11, wherein the Fc domain is a modified Fc, and the modified Fc prolongs the half-life of the TL1A binding protein compared to a TL1A binding protein not containing the modified Fc domain.

13. The TL1A binding protein of claim 11 or claim 12, wherein the Fc domain comprises amino acid modifications of L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

14. A TL1A binding antibody, wherein the TL1A binding antibody specifically binds to a TL1A polypeptide comprising SEQ ID NO: 2493 at any one of the following amino acid residues: Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123 and Arg 156.

15. The TL1A binding antibody of claim 14, wherein the TL1A binding antibody specifically binds to the TL1A sequence at amino acid residues Val102, Arg103, Gln104, Glu120, Glu122, Leu123 and Arg156.

16. The TL1A-binding protein or TL1A-binding antibody as described in any one of claims 1-15, wherein the TL1A-binding protein has a Kc of less than about 0.5 nanomolars (nM). D Combined with TL1A.

17. A TL1A-binding protein, said TL1A-binding protein comprising: a) Heavy chain variable region (VH), the heavy chain variable region comprising (i) CDR1 having an amino acid sequence according to any one of SEQ ID NO: 1-4 and 313-421, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 1-4 and 313-421, (ii) CDR2 having an amino acid sequence according to any one of SEQ ID NO: 11-14 and 422-530, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 11-14 and 422-530, and (iii) CDR3 having an amino acid sequence according to any one of SEQ ID NO: 21-24 and 531-639, or having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 21-24 and 531-639; and b) A light chain variable region (VL) comprising (i) a CDR1 having an amino acid sequence according to any one of SEQ ID NO: 31-34 and 640-748, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 1-4 and 313-421, (ii) a CDR2 having an amino acid sequence according to any one of SEQ ID NO: 41-44 and 749-857, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 41-44 and 749-857, and (iii) a CDR3 having an amino acid sequence according to any one of SEQ ID NO: 51-54 and 858-966, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 51-54 and 858-966.

18. The TL1A binding protein of claim 17, wherein the VH comprises a sequence having at least 80% sequence identity with any one of the amino acid sequences of SEQ ID NO: 181-184 and 2275-2383, and the VL comprises a sequence having at least 80% sequence identity with any one of the amino acid sequences of SEQ ID NO: 191-194 and 2384-2492.

19. The TL1A binding protein of claim 17 or claim 18, wherein... The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 181, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 191; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 182, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 192; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 183, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 193; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 184, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 194; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2283, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2392; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2303, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2412; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2307, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2416; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2311, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2420; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2313, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2422; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2316, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2425; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2327, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2436; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2333, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2442; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2334, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2443; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2335, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2444; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2350, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2459; The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2356, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2465; or The VH contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2362, and the VL contains a sequence having at least 80% sequence identity with the amino acid sequence of SEQ ID NO: 2471.

20. A TL1A-binding protein, said TL1A-binding protein comprising: The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 1, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 1, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 11, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 11, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 21, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 21; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 31, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 31, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 41, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 41, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 51, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 51; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 2, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 2, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 12, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 12, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 22, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 22; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 32, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 32, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 42, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 42, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 52, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 52; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 3, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 3, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 13, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 13, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 23, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 23; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 33, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 33, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 43, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 43, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 53, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 53; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 4, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 4, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 14, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 14, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 24, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 24; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 34, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 34, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 44, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 44, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 54, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 54; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 321, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 321, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 430, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 430, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 539, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 539; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 648, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 648, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 757, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 757, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 866, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 866; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 341, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 341, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 450, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 450, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 559, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 559; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 668, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 668, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 777, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 777, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 886, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 886; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 345, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 345, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 454, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 454, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 563, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 563; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 672, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 672, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 781, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 781, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 890, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 890; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 349, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 349, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 458, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 458, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 567, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 567; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 676, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 676, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 785, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 785, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 894, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 894; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 351, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 351, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 460, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 460, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 569, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 569; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 678, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 678, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 787, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 787, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 896, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 896; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 354, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 354, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 463, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 463, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 572, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 572; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 681, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 681, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 790, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 790, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 899, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 899; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 365, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 365, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 474, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 474, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 583, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 583; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 692, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 692, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 801, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 801, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 910, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 910; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 371, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 371, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 480, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 480, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 589, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 589; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 698, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 698, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 807, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 807, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 916, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 916; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 372, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 372, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 481, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 481, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 590, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 590; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 691, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 691, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 808, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 808, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 917, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 917; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 373, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 373, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 482, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 482, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 591, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 591; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 700, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 700, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 809, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 809, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 918, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 918; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 388, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 388, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 497, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 497, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 606, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 606; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 715, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 715, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 824, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 824, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 933, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 933; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 394, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 394, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 503, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 503, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 612, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 612; as well as A light chain variable region (VL) comprising (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 721, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 721, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 830, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 830, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 939, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 939; or The heavy chain variable region (VH) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 400, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 400, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 509, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 509, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 618, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 618; as well as The light chain variable region (VL) comprises (i) a CDR1 having the amino acid sequence according to SEQ ID NO: 727, or a CDR1 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 727, (ii) a CDR2 having the amino acid sequence according to SEQ ID NO: 836, or a CDR2 having one or two amino acid substitutions compared to the sequence of SEQ ID NO: 836, and (iii) a CDR3 having the amino acid sequence according to SEQ ID NO: 945, or a CDR3 having one or two amino acid substitutions compared to the sequence of SEQ ID NO:

945.

21. A TL1A-binding protein, said TL1A-binding protein comprising a heavy chain variable region (VH), said heavy chain variable region comprising: (i) A CDR1 having an amino acid sequence according to any one of SEQ ID NO: 1-4 and 313-421, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 1-4 and 313-421; (ii) A CDR2 having an amino acid sequence according to any one of SEQ ID NO: 11-14 and 422-530, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 11-14 and 422-530; and (iii) A CDR3 having an amino acid sequence according to any one of SEQ ID NO: 21-24 and 531-639, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 21-24 and 531-639.

22. A TL1A-binding protein, said TL1A-binding protein comprising a light chain variable region (VL), said light chain variable region comprising: (i) A CDR1 having an amino acid sequence according to any one of SEQ ID NO: 31-34 and 640-748, or a CDR1 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 31-34 and 640-748; (ii) A CDR2 having an amino acid sequence according to any one of SEQ ID NO: 41-44 and 749-857, or a CDR2 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 41-44 and 749-857; and (iii) A CDR3 having an amino acid sequence according to any one of SEQ ID NO: 51-54 and 858-966, or a CDR3 having an amino acid sequence having one or two amino acid substitutions compared to any one of SEQ ID NO: 51-54 and 858-966.

23. The TL1A binding protein of any one of claims 17-20, wherein the TL1A binding protein is an antibody, the antibody comprising an IgG1, IgG2, or IgG4 immunoglobulin Fc domain.

24. The TL1A binding protein of claim 23, wherein the Fc domain is a modified Fc, and the modified Fc prolongs the half-life of the TL1A binding protein compared to a TL1A binding protein not containing the modified Fc domain.

25. The TL1A binding protein of claim 24, wherein the modified Fc domain comprises amino acid modifications L234A / L235A (LALA) and / or M252Y, S254T and T256E (YTE).

26. A TL1A binding antibody, wherein the TL1A binding antibody specifically binds to a TL1A polypeptide comprising SEQ ID NO: 2493 at any one of the following amino acid residues: Lys243, Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Ile233, Asp232, Met158, Arg156, Trp119, His118, Lys111, Phe110, His109, Gln108, Thr107, Pro106, Thr105, Gln104, Arg103, Val102, and Val101.

27. A TL1A binding antibody, wherein the TL1A binding antibody specifically binds to a TL1A polypeptide comprising SEQ ID NO: 2493 at any one of the following amino acid residues: Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Gln104, and Arg103.

28. The TL1A-binding protein of any one of claims 17-27, wherein the TL1A-binding protein has a Kc of less than about 0.5 nanomolars (nM). D Combined with TL1A.

29. A method of treating an inflammatory disease in a patient in need, the method comprising administering, subcutaneously or intravenously, an effective amount of TL1A-binding protein as described in any one of claims 1-28, or TL1A binding antibodies that specifically bind to the TL1A polypeptide containing SEQ ID NO: 2493 at any of the following amino acid residues: Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Gln104, and Arg103, or TL1A binding antibodies that specifically bind to the TL1A peptide containing SEQ ID NO: 2493 at any of the following amino acid residues: Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123, and Arg 156.

30. The method of claim 29, wherein the inflammatory disease is a gastroenteritis or inflammatory bowel disease.

31. The method of claim 30, wherein the inflammatory bowel disease is Crohn's disease.

32. The method of claim 31, wherein the inflammatory bowel disease is ulcerative colitis.

33. The method of claim 32, wherein the inflammatory disease is psoriasis, psoriatic arthritis, or hidradenitis suppurativa.

34. The method of any one of claims 29-33, wherein the application of the TL1A binding protein is subcutaneous.

35. The method of any one of claims 29-33, wherein the administration of the TL1A binding protein is intravenous.

36. The method of any one of claims 29-33, wherein the method comprises administering the TL1A binding protein to the patient two or more times at intervals of about 2 weeks to about 12 weeks or longer.

37. A composition comprising the TL1A binding protein as described in any one of claims 1-28 and a pharmaceutically acceptable carrier.

38. An injectable liquid composition comprising the TL1A binding protein as described in any one of claims 1-28 and a pharmaceutically acceptable carrier.

39. An isolated nucleic acid, said isolated nucleic acid encoding a TL1A binding protein as described in any one of claims 1-28.

40. A recombinant host cell comprising the isolated nucleic acid as described in claim 39.

41. A method for producing a TL1A binding protein, wherein the TL1A binding protein specifically binds to a TL1A polypeptide comprising SEQ ID NO: 2493 at any one of the amino acid residues in Table 12, 13 or 14, wherein the TL1A antigen-binding protein is an antibody.

42. The method of claim 41, wherein the TL1A binding antibody specifically binds to the TL1A polypeptide comprising SEQ ID NO: 2493 at any of the following amino acid residues: Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Gln104, and Arg103.

43. The method of claim 41, wherein the TL1A binding antibody specifically binds to the TL1A polypeptide comprising SEQ ID NO: 2493 at any of the following amino acid residues: Val 102, Arg 103, Gln 104, Glu120, Glu 122, Leu 123, and Arg 156.

44. A method for obtaining an antibody that specifically binds to certain epitope portions of a TL1A sequence comprising SEQ ID NO: 2493 or SEQ ID NO: 2494, wherein the method comprises: a) Assess whether the antibody specifically binds to certain epitope moieties, wherein said certain epitope moieties i) Recognized by the antibody as described in any one of claims 1-28; or ii) Having amino acid residues Val 102, Arg 103, Gln 104, Glu 120, Glu 122, Leu 123 and Arg 156 of SEQ ID NO: 2493, or iii) The amino acid residues Lys240, Thr239, Tyr238, Asp237, Val236, Leu235, Ser234, Gln104, and Arg103 of SEQ ID NO: 2493, and b) Isolate or select the antibodies that bind to the said epitope portions.

Images